assay_id	description	method	assay_type
868	Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%		B
2027	Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta		B
2430	Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor		B
3306	Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand		B
3703	In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined		B
14978	Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events		F
27772	Antagonism of NECA-induced stimulation of adenylate cyclase activity in human platelet membranes at A2-adenosine receptor; value ranges from 21-30		F
28218	Percent remaining of radioligand [3H]DPCPX binding to human adenosine A1 receptor at 10 uM		B
30534	Concentration required for 50% inhibition of [3H]NECA binding on rat brain adenosine A2 receptor		B
31060	Displacement [3H]-CGS-21,680 from Adenosine A2A receptor in rat striatal membrane.		B
31220	Saturation binding of human Adenosine A2A receptor (H250N) at pH 6.8		B
31960	Displacement of [3H]-SCH- 58261 from human adenosine A2A receptor expressed in CHO cells; range 65-92		B
33326	Binding affinity towards human alpha-2 adrenergic receptor		B
33373	Binding affinity towards Alpha-2B adrenergic receptor; ND=No data		B
36274	Displacement of DHT from human androgen receptor		B
37110	Antagonist activity of compound against Beta-1 adrenergic receptor in isolated guinea pig left atria		F
37378	Evaluated for its agonist activity and the binding affinity against human Beta-1 adrenergic receptor in membranes from chinese hamster ovary cell		B
37727	Median survival time (% T/C) after ip administration of a dose of 4 mg/kg/day in B-16 melanoma in mice		F
40592	Percent growth of breast MCF-7 cell line at compound concentration 10e-6 was determined		F
41183	Minimum protective concentration against beta-lactamase in Staphylococcus aureus (95 strain)		F
44934	Effective dose required to produce an increase in dP/dt by 1500 mmHg/s from that of the control in the anesthetized cats.		F
47207	Effect of intravenous infusion on diastolic pressure in Anesthetized cats at a dose of 1.50 mg/kg at 10 min		F
47961	Displacement of [125I]- BH-CCK-8 from Cholecystokinin type B receptor of guinea pig cortex		B
49482	The ability to reversibly bind to DNA using ethidium bromide displacement assay was reported as apparanet DNA binding constant for Coliphage T4 DNA	ethidium bromide displacement assay	B
52280	Binding constant for DNA by ethidium bromide displacement	ethidium bromide displacement	B
52441	Compound was evaluated for DNA-binding affinity using poly[d(GC)]2		B
52456	Ability to interact with DNA was assessed by a DNA/ethidium bromide dye displacement assay, expressed as DC50 for polydAdT	ethidium bromide dye displacement assay	B
55304	Selective index for Dihydrofolate reductase was determined by IC50(rat liver) / IC50(Toxoplasma gondii)		B
60370	Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2		B
60815	In vitro for its ability to displace [3H]- spiperone from cloned human Dopamine receptor D4 expressed in CHO cells		B
60971	pKi value for Dopamine receptor D2 binding site		B
61299	D2 receptor functional activity was measured through reversal of quinpirole inhibited, forskolin stimulated cAMP production from whole cells		F
63532	Binding affinity measured in CHO cells stably transfected with the human endothelin B receptor		B
64839	Effect on the activity of elastase was determined		F
66816	Minimum inhibitory concentration required for antibacterial activity against Escherichia coli 10418		F
66845	Relative binding affinity (RBA) for estrogen receptor at 0C		B
67359	Functional ERalpha receptor activity in transcriptional activation assay in MCF-7 cells	transcriptional activation assay	B
68591	Displacement of [3H]GABA from rat brain Gamma-aminobutyric acid receptor		B
68829	Cell growth of friend erythroleukemia cells measured as percentage of control on day 6 at a concentration of 105 mM		F
70429	Concentration required to displace 50% of a radiolabeled farnesyltransferase inhibitor from FPTase in cultured Ha-Ras transformed RAT1 cells		F
73696	Irreversible antagonism to morphine was evaluated after 30 min incubation of GPI with the compound at 1000 nM conc.		F
75628	Cytotoxicity against a human colon cancer cell line (HCT116 cells) was reported		F
78652	Inhibitory activity against HL 60 cells		F
82611	Antiviral activity against herpes simplex virus type I was measured at 5 uM concentration.		F
85499	Histamine H2 receptor antagonistic activity at a concentration of 0.3 and 0.1 uM on the isolated guinea pig right atrium.		F
86691	Ratio of Kreact to that of Kinact was determined on human leukocyte elastase(HLE)		B
87333	Potency relative to progesterone in reducing the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells		F
88744	Cytotoxic activity against human neuroblastoma IMR32 cells which over-express somatostatin receptors; na is not active		F
92634	Effective dose to inhibit FasL-induced apoptosis in Jurkat cells (Type II); NE=no effect		F
95086	Concentration inhibiting radiolabeled spermidine transport in L1210 cells.		F
96879	Inhibition of glycogen synthesis in rat skeletal muscle L6 cells (inactive)		F
102351	Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method.	MIT method	F
102812	Antiprotozoal activity (functional assay) using Mauden-Downing bovine kidney (MDBK) host cells infected with Eimeria tenella		F
103748	Inhibitory concentration against AD169 strain of HCMV in MRC5 cells		F
107760	Evaluated for survival time of P388 Leukemia implanted female CDF1 Mice at a dose of 25 mg/kg		F
110077	In vivo anticonvulsant activity in male albino mice using the maximal electroshock (MES) test after intraperitoneal administration; value ranges from 85.7-151	maximal electroshock (MES) test	F
117836	Nephrotoxicity upon intragastric administration was assessed in mice kidney as proximal tublar necrosis deep in the cortex at a dose of 10 mM		F
122514	Inhibition of Rauscher leukemia virus in female BALB/c mice. Compound is administered perorally at 125 mg/kg for 5 days a week for 4 weeks (exp 1); treated/control= 46.8/46.0		F
125044	Uterotrophic activity in immature mouse		F
139241	Binding affinity towards cloned human muscarinic acetylcholine receptor M4 stably expressed in CHO-K1 cells using [3H]N-methylscopolamine		B
140142	The compound was tested for binding affinity against muscarinic acetylcholine receptor using QNB as radioligand		B
140186	Compound was evaluated for its binding affinity towards M2 receptor in rat brainstem		B
143173	Tested for displacement of radioligand [3H]naloxone from opiate receptor; ND, no data		B
143180	Concentration required to inhibit opiate receptor using radioligand [3H]- Etorphine		B
143997	Concentration that inhibited 50% of binding of 125 I -PYY ligand to human Neuropeptide Y receptor type 5		B
145392	Inhibition of binding of [3H]diprenorphine to cloned human Opioid receptor kappa 1 expressed in CHO cell membrane		B
146271	Selectivity ratio is IC50 value of mu-opioid receptor to that of delta-opioid receptor		B
146556	The compound was tested for the ability to displace mu-receptor specific radioligand [3H]DAGO		B
146904	Binding affinity against Opioid receptor delta 1 of rat brain using [3H]-nor BNI as radioligand.		B
147295	Ability to stimulate binding to delta-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes, blocked with 20 nM naltrindole (NTI); NS= no stimulation	GTP-gamma -S-binding assay	B
148037	Antitumor activity against P338 leukemia cells measured as toxic level at 3.12 mg/kg, ip optimal dose on days 1-5 in mice		F
148551	Compound was evaluated for Inhibition of binding of [3H]- DAMGO at Rat brain mu receptor binding site, Expt-2		B
149007	Compound was tested for binding affinity towards Opioid receptor mu 1 by displacing [3H]DAGO radioligand in rat brain P2 synaptosomes membranes.		B
149058	Inhibition of binding of [3H]oxytocin to rat uterine oxytocin receptor		B
151167	MST of treated animal over control when administered at a dose of 5 mg/kg intravenously on Q01Dx01 treatment schedule		F
151851	In vitro inhibitory activity against human PANC-1 pancreatic tumor; Active		F
154359	Binding affinity towards peroxisome proliferator activated receptor gamma (PPAR gamma); weakly active		B
154707	Binding affinity was measured as selectivity for sigma-1 site over phencyclidine (PCP) receptor in rat using [3H]TCP as radioligand at 10 uM		B
155626	In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 (CDC/Sierra Leone I); Not active		F
157141	Accumulation coefficient of chloroquine at 1 uM-10 uM of DEEA against Plasmodium falciparum W2; Range is from 14-56		F
157538	Binding affinity against HIV-Protease was determined		B
157813	Displacement of [3H]PGE-2 from human Prostaglandin E receptor EP3 expressed in CHO-KI cells		B
159810	Apparent binding constant was determined by ethidium displacement assay in poly (dG-dC)	ethidium displacement assay	B
160631	Displacement of [3H]PDBu from protein kinase C beta C1b domain		B
161303	Displacement of [3H]- PDBu from Protein kinase C gamma C1b domain		B
166452	Concentration required to decrease 25% of blood pressure in rat; ED25 not reached at 1.0 mg/kg iv		F
167325	Opioid agonist activity by measuring the analgesia produced after 10 mg/kg administration in rats; none		F
167428	Effect of pretreatment with alpha-MPT on the rotational behavior induced by the compound (5 mg/kg, sc) in rats with 6-OHDA induced lesions (indicates that it acted directly on DA receptors)		F
169740	Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 0.312 mg/kg in fasted rats		F
170803	Percent decrease in angiotensin I pressor response was measured in rat, administered intravenously at dose 0.010 mg/kg		F
185374	Effect on urinary excretion potassium and sodium after oral administration of 25 mg/kg to rats(potassium and sodium excretion in control rat is 0.146+/-0.017)		F
185993	Maximal reduction in percent (Partial response) of DOPA accumulation rat hemispheres at highest test dose of 61 uM/Kg (po); Inactive		F
186424	Dose-dependent protective activity at 10 mg/kg (po, b.i.d.) on cartilage damage in hind paws of CIA-rats		F
189479	Percentage of animals emitting 50 presses on the LSD appropriate lever during the test period in rat at 0.02 mg/kg(0.046 uM/kg)		F
195972	In vitro binding affinity for human renin at pH 7.2		B
196770	Inhibition of 3[H]9-cis-retinoic acid binding to Retinoic acid receptor RXR-alpha expressed in CV-1 cells		B
196812	Effect on replication of FIV 34TF10env in chronically infected feline glial cell lines G355-5 at 1000 nM conc; RT activity per ug/mL of protein concentration		F
203511	In vitro minimum inhibitory concentration against Staphylococcus epidermis ATCC 12228		F
210907	The compound was tested for relative binding affinity against calf uterine receptor using [3H]estradiol as radioligand		B
212438	inhibition of the growth of renal cancer(UO-31) cell line		F
213894	Antibacterial activity against Vibrio cholerae 0139		F
215016	Binding affinity towards rat kidney Vasopressin V2 receptor by using functional assay		B
220135	Inhibition of aggregation of human gel-filtered platelets measured by light transmittance method at 37 degrees C.	light transmittance method	F
222348	5-HTP accumulation in limbic system was determined in vivo		F
223059	Compound was evaluated for the binding constant for association with nicotinic acetylcholine receptor (nAChR)		B
229363	Ratio of cytochrome P450 19A1 Ki for 6-alpha substituted steroid relative to 6-beta substitution		B
229570	Selectivity as ratio of pA2 value against alpha-2 receptor to that of alpha-1 receptor.		B
302265	Binding potency towards Delta opioid receptor of mouse vas deferens		B
303054	Binding affinity against Synechocystis strain PCC6803 DXP reductoisomerase		B
303088	Binding affinity towards human D2 short receptor using [3H]spiperone expressed in CHO cells		B
304048	Binding affinity towards human 5-hydroxytryptamine receptor 6 expressed in HeLa cells using the radioligand [3H]LSD		B
305518	Binding affinity for Prostaglandin G/H synthase 2 (COX-2)		B
306826	In vitro inhibitory concentration against binding of the [3H]glycine to strychnine-insensitive glycine binding sites of rat N-methyl-D-aspartate glutamate receptor		B
308660	Dissociation constant was measured against HIV-1 RNA construct F (present in HIV-1 RRE IIB RNA region); N.B. = no measurable binding		F
311495	Growth inhibition against human pancreas carcinoma cell line (BxPC-3); (NT = Not tested)		F
311581	Cytotoxicity against A549 cell line		F
313538	Ratio of the MIC value of the Mycobacterium tuberculosis ) isoniazid resistant strain to H37Rv strain was determined		F
314632	Concentration of C22:2 ceramide in liver of D-galactosamine treated rats after 18 hr at dose of 1 g/kg intraperitoneally		F
320862	Inhibition of [3H]CGS-21680 binding to adenosine A2a receptor of human striatal membrane		B
320918	In vitro binding affinity towards cloned human 5-HT6 receptor using [3H]5-carboximidotryptamine as radioligand: nd=Not determined		B
325472	Percentage inhibition of [3H]NECA binding to cloned human adenosine A2A receptor expressed in CHO cells at 10 uM		B
327286	Displacement of [125I]-His5, D-Tyr6]GnRH from mutant GnRHR, GnRHR S186D		B
328483	Increase of HDL level in cholesterol-fed male rats by ultracentrifugation method at 55 mg/kg/day relative to control	ultracentrifugation method	F
330729	Effect on DBH activity in presence of dopamine by measuring Noradrenaline level		F
346375	Antiproliferative activity against resistant CCRF-CEM/VBL cell line		F
401203	Cytotoxicity against HEK293 cells relative to control		F
422259	Antibacterial activity against Bacillus subtilis		F
426791	Antibacterial activity against methicillin-resistant Staphylococcus aureus B42876		F
427950	Effect on ratio of total cholesterol to HDL cholesterol in lean Wistar rat at 70 mg/kg/day relative to control		F
428740	Displacement of 3H]RX821002 from rat cortex adrenergic alpha-2 receptor		B
431066	Displacement of [3H]SR141716A from human CB1 receptor expressed in CHO cells at 10 uM		B
432490	Antiviral activity against hepatitis C virus		F
434771	Binding affinity to calf thymus double stranded DNA		B
435199	Displacement of [3H]MK-801 from rat brain NMDA receptor		B
439762	Cytotoxicity against human LNCaP cells after 72 hrs by SRB assay	SRB assay	F
440187	Binding affinity to GAPDH in human erythrocytes		B
441160	Antimicrobial activity against Escherichia coli MC4100 assessed as inhibition zone at >2 mg/mL		F
441740	Growth inhibition of DLA cells at 62.5 ug/mL after 3 hrs		F
442702	Inhibition of TNF-alpha-induced E-selectin expression in HUVEC cells at 90 ug/ml after 2 hrs by flow cytometry	flow cytometry	F
445591	Binding affinity to human ERbeta		B
447281	Binding affinity to human ERalpha		B
448621	Binding affinity to human ERbeta		B
449795	Displacement of [3H]oxytocin from human oxytocin receptor expressed in CHO cells at 1000 nM		B
466333	Displacement of [3H]estradiol from human recombinant ERbeta relative to estradiol		B
473897	Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in spleen at 25 mg/kg, ip after 10 days		F
474423	Displacement of [3H]R5020 from human PR in human T47D cells by whole cell assay		B
475573	Increase in acetylated alpha tubulin level in human HCT116 cells at 10 uM after 24 hrs relative to control		F
475911	Effect on Phorbol 12-myristate 13-acetate-induced macropinocytosis in mouse J774 macrophage cells at 20 uM by video microscopy	video microscopy	F
476688	Binding affinity to CB2 receptor		B
477028	Antibacterial activity against Staphylococcus aureus ATCC 25923 at 400 ug/disc after 18 hrs by disc diffusion assay	disc diffusion assay	F
480847	Antitumor activity against Agrobacterium tumefaciens-induced crown gall tumors assessed as inhibition of tumor development in potato by crown gall tumor potato disk test	crown gall tumor potato disk test	F
486467	Phytotoxicity against Johnsongrass assessed as leaf necrotic lesions at 100 ug by detached leaf spot method	detached leaf spot method	F
490012	Ratio of Kcat to Km for HIV1 reverse transcriptase assessed as nucleotide excision activity in presence of 0.5 uM dCTP		B
493450	Displacement of [3H]Ro-154513 from benzodiazepine binding site of GABAA alpha-4-beta-2-gamma-2 receptor expressed in HEK293T cells		B
494280	Binding affinity to calf thymus DNA assessed as circular dichrosim at 10 uM	circular dichrosim	B
502968	Cytotoxicity against human SNB19 cells		F
504534	Anxiolytic-like activity in ddY mouse assessed as ambulatory activity at 1 mg/kg, po for 7 days measured 24 hrs after final drug administration assessed per 5 mins by tilting type ambulometer test	tilting type ambulometer test	F
506850	Cytotoxicity against human MDA-MB-435 cells		F
507009	Cytotoxicity against human A2780 cells		F
507750	Antiparasitic activity against Toxoplasma gondii infected in HFF cells at 1 uM after 24 hrs by [3H]uracil incorporation assay relative to control	[3H]uracil incorporation assay	F
507889	Inhibition of cartilage damage in New Zealand white rabbit osteoarthritis model assessed as reduction of cartilage lesion on femoral condyles at 30 mg/kg, po twice daily after 5 weeks relative to control		F
509571	Displacement of [3H]MRS1754 from human adenosine A2B receptor expressed in CHO cell membrane		B
512423	Displacement of radioligand from adrenergic alpha2A receptor		B
513447	Cytotoxicity against human HOP62 cells assessed as age growth inhibition at 100 uM after 48 hrs by sulforhodamine B assay	sulforhodamine B assay	F
514923	Inhibition of luciferin binding site of Photuris pennsylvanica luciferase by competitive KinaseGlo Plus Max luminescent assay	competitive KinaseGlo Plus Max luminescent assay	B
516355	Displacement of [3H]estradiol from human recombinant estrogen receptor alpha by radiometric assay relative to estradiol		B
518848	Inhibition of PDGFRbeta by Ambit binding assay	Ambit binding assay	B
522532	Antifungal activity against Candida tropicalis isolate 0022-021 after 24 hrs by CLSI M27-A2 broth microdilution method in presence of RPMI 1640 medium	CLSI M27-A2 broth microdilution method	F
525851	Displacement of [3H]NMS from human cloned muscarinic M5 receptor expressed in insect Sf9 cells		B
526824	Antibacterial activity against Staphylococcus epidermidis NCIMB 8853 by microdilution method	microdilution method	F
532315	Binding affinity to Plasmodium falciparum spermidine synthase by saturation transfer difference-NMR experiment	saturation transfer difference-NMR experiment	B
533302	Cytotoxicity against human Hs 633T cells at 2 uM assessed as fraction of viable cells after 72 hrs relative to control		F
535635	Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in HEK293 cells		B
536900	Binding affinity to bone assessed as drug level bound to cattle bone meal powder by fluorescence assay	fluorescence assay	B
537086	Binding affinity to human KHS1		B
538318	Displacement of [3H]NECA from human cloned adenosine A3 receptor expressed in human HeLa cells		B
544150	Cytotoxicity against human MCF7 cells by SRB assay	SRB assay	F
548548	Inhibition of LPS and INF-gamma-induced iNOS mRNA expression in mouse RAW264.7 cells by RT-PCR analysis	RT-PCR analysis	F
549577	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	MTT assay	F
554919	Decrease in CGD gene ortholog accession number orf19.6211 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	microarray based transcriptional profiling	F
555490	Decrease in CGD gene ortholog accession number orf19.409 expression in Candida parapsilosis CLIB214 at 50 uM after 2 hrs by microarray based transcriptional profiling relative to control	microarray based transcriptional profiling	F
559547	Displacement of [3H] 2-((1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-5-(2-methyloctan-2-yl)phenol from human CB2 receptor expressed CHO-K1 cells by liquid scintillation counting	liquid scintillation counting	B
560038	Agonist activity at human CB1 receptor expressed in SF9 cells assessed as inhibition of CP-55940-stimulated GTP binding		B
562670	Displacement of 4-methylumbelliferydiacetyl-chitobiose from Serratia marcescens ChiB		B
572761	Displacement of F-BakBH3 from Bfl-1 by fluorescence polarization assay	fluorescence polarization assay	B
574044	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus isolate 703 bloodstream form isolated from patient with endocarditis assessed as bacterial survival rate at 20 ug/ml after 2 hrs		F
576733	Antifungal activity against 1.04 x 10'8 CFU Candida glabrata isolate 4293 infected in CD1 mouse assessed as inhibition of regrowth in fungal burden in kidney at 1 mg/kg/day, ip administered from day 1 to day 2 post viral challenge measured on day 7 postinfection		F
576943	Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM605 in mouse J774A1 cells isolated from colonic mucosal biopsies of patient with Crohn's disease assessed as intracellular killing of bacteria at 18 ug/ml after 6 hrs		F
580428	Antibacterial activity against Clostridium difficile CD5 expressing tet(W) gene		F
580793	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate 13		F
588130	Displacement of [3H]spiperone from human cloned dopamine D3 expressed in CHO cells		B
588548	Binding affinity to Escherichia coli pUC19 DNA assessed as form 1 DNA level at 0.130 mM after 8.08 hrs by agarose gel electrophoresis	agarose gel electrophoresis	B
592537	Inhibition of radioligand binding to human adrenergic Alpha-2C receptor at 10 uM after 60 mins		B
597913	Displacement of [3H]SR141716A from rat brain CB1 receptor		B
602018	Displacement of [3H]AMPA from wild type rat GluR2 S1S2 ligand binding core		B
602453	Binding affinity to human ALK at 200 nM by cell-based competition binding assay relative to control in presence of DTT		B
603084	Agonist activity at human 5HT1A receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[35S]GTPgammaS binding assay	F
615712	Antilipolytic activity in po dosed rat assessed as reduction plasma free fatty acids levels		F
619315	Antiproliferative activity against human CCRF-CEM cells at 10 uM assessed as cell growth inhibition relative to control		F
620370	Cytotoxicity against human NCI-H23 cells assessed as cell growth at 0.1 uM after 1 to 11 days by MTT assay	MTT assay	F
623020	Growth inhibition of human HCC2998 cells at 100 nM after 96 hrs by MTT assay	MTT assay	F
626035	Inhibition of capsaicin-induced vasodilation in orally dosed rhesus monkey at 5.5 uM plasma level		F
627749	Binding affinity to PPARgamma		B
631920	Cell cycle arrest in human A2780 cells assessed as accumulation at subG1 phase at 0.5 uM after 24 hrs by propidium iodide staining-based FACS analysis	propidium iodide staining-based FACS analysis	F
638891	Displacement of [3H](+)-pentazocine from sigma1 opioid receptor from guinea pig brain cortex at 1 uM after 150 mins by scintillation counting	scintillation counting	B
641661	Growth inhibition of human HL-60(TB) cells after 48 hrs by sulforhodamine B assay	sulforhodamine B assay	F
642034	Agonist activity at human C3a receptor in human U937 cells assessed as induction of intracellular calcium release		F
642096	Displacement of [3H]methylspiperone from human cloned 5HT2A receptor expressed in HEK293 cells at 1 uM after 90 mins by liquid scintillation counting	liquid scintillation counting	B
643730	Antagonist activity at mouse cloned Smo receptor expressed in NIH-3T3 cells co expressing Gli1 binding site after 15 hrs by luciferase reporter gene assay	luciferase reporter gene assay	B
645376	Antimicrobial activity against Beta-lactamase-negative, ampicillin-resistant Haemophilus influenzae with Ile449Val, Asn526Lys substitutions in penicillin-binding protein 3 by broth microdilution method	broth microdilution method	F
648420	Ratio of acyclovir EC50 to compound EC50 for HSV 2 infected in african green monkey Vero cells		F
649008	Agonist activity at muscarinic M4 receptor in wild type mouse hippocampal CA1 pyramidal neuron assessed as increase in carbachol-induced reduction in excitatory postsynaptic current at 5 uM by whole-cell electrophysiology relative to control	whole-cell electrophysiology	F
651193	Binding affinity to GGTase-1 F52Y/Y126T mutant assessed as prenylation of RhoA GTPase by Western blot method	Western blot method	B
651820	Cytotoxicity against human KB cells after 72 hrs by MTT assay	MTT assay	F
653926	Binding affinity to (CAG-CAG) trinucleotide repeats at 120 uM by ESI-TOF mass spectroscopy	ESI-TOF mass spectroscopy	B
656702	Ratio of IC50 for inhibition of HIV1 HXB2 gp120-mediated viral infusion into HEK293 cells in presence of 45 mg/ml human serum albumin to IC50 for inhibition of HIV1 HXB2 gp120-mediated viral infusion into HEK293 cells in absence of 45 mg/ml human serum albumin		B
658554	Binding affinity to human recombinant GABAA receptor		B
660786	Cell cycle arrest in human U2OS cells overexpressing human KRAS2 assessed as accumulation at G1 phase at 15 nM after 48 hrs by CMV-GFP reporter assay method	CMV-GFP reporter assay method	F
665576	Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells		B
671559	Antiviral activity against Influenza A virus (A/Hong Kong/1073/99(H9N2)) infected in MDCK cells assessed as log reduction in viral titer at 960 uM after 48 hrs by MTT assay	MTT assay	F
672622	Antiplasmodial activity against Plasmodium falciparum D10 ATCC 563 after 72 hrs by SYBR green assay	SYBR green assay	F
677042	FIC index, ratio of MIC for Pseudomonas aeruginosa 100609 in presence of 250 ug/ml polyethylenimine to MIC for Pseudomonas aeruginosa 100609		F
681843	Antimicrobial activity against Legionella pneumophila ATCC 33153 infected in THP1 cells after 48hrs		F
686801	Displacement of [125I]-C5a Anaphylatoxin from anaphylatoxin C5a at 1 to 3 uM		B
687324	Displacement of [3H]ZM241385 from human adenosine A2B receptor transfected in CHO cells after 60 mins by scintillation counting	scintillation counting	B
691129	Antimicrobial activity against Staphylococcus epidermidis C960 by broth microdilution method	broth microdilution method	F
695454	Antibacterial activity against Salmonella enterica serovar Enteritidis assessed as percent susceptible isolates by broth microdilution method	broth microdilution method	F
695627	Binding affinity to CGT ACA GTG DNA sequence assessed as change in melting temperature by thermal denaturation assay	thermal denaturation assay	B
700796	Inhibition of human MAPKAP-K3 at 10 uM after 60 mins by TR-FRET assay	TR-FRET assay	B
701191	Inhibition of p110alpha/p85alpha at 10 uM after 60 mins by TR-FRET assay	TR-FRET assay	B
705805	Ratio of EC50 for HIV1 TM harboring L10I/K14R/R41K/M46L/I54V/L63P/A71V/V82A/L90M/I93L in protease encoding region to EC50 for HIV1 ERS104pre		F
708208	Trypanocidal activity against Trypanosoma brucei brucei 667 infected in mouse assessed as average day of relapse of trypanosomal infection at 25 mg/kg, ip BID for 14 days		F
708614	Bactericidal activity against Pseudomonas aeruginosa isolate 956 at 1/4 times MIC after 24 hrs by time kill analysis		F
709641	Antibacterial activity against Escherichia coli DSM 498		F
713773	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay	hemagglutininin titer assay	F
715883	Cytotoxicity against human HNXF 536L cells at 10 ug/ml relative to control		F
719615	Antimicrobial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method	broth microdilution method	F
720628	Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay in presence of 4-oxo-2,2,6,6,-tetramethyl-1-piperidinyloxy	[3H]hypoxanthine incorporation assay	F
724668	Antibacterial activity against 1 x 10'4 CFU Streptococcus pneumoniae ATCC 6305 after 18 hrs by CLSI 2-fold agar dilution method	CLSI 2-fold agar dilution method	F
725903	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155K mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	luciferase reporter assay	F
729351	Effect on glutathione peroxidase expression in human A549 cells assessed as transcript level at 662 nM after 24 hrs by RT-qPCR analysis relative to untreated control	RT-qPCR analysis	F
732024	Antimicrobial activity against 5-fluorocytosine resistant Candida glabrata isolate TE34-78 harboring Fcr1 L136R mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method	broth microdilution method	F
735687	Induction of change in cytochrome c protein level in iTRAQ114 labelled secreted fraction of drug-resistant Aspergillus fumigatus EMFR-S678P at 0.12 ug/ml after 24 hrs in YPD medium by MS (MS/MS) analysis relative to control	MS (MS/MS) analysis	F
735749	Antibacterial activity against Salmonella by broth macrodilution method	broth macrodilution method	F
743655	Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of syncytia formation		F
744077	Inhibition of MAPK14 at 25 uM by TR-FRET assay	TR-FRET assay	B
745305	Binding affinity to human telomeric (5'-FAM-GGG TTA GGG TTA GGG TTA GGG-TAMRA-3') DNA assessed as concentration required to cause half maximal change in melting temperature by FRET-melting assay (Rvb = 59.4 degC)	FRET-melting assay	B
746641	Induction of apoptosis in human Raji cells assessed as late apoptotic or secondary necrotic cells at 10 uM after 24 hrs by measuring phosphatidylserine translocation using annexin V-FITC/propidium iodide staining by FACS (Rvb = 2.2 %)	annexin V-FITC/propidium iodide staining by FACS	F
746775	Displacement of [3H]AVP from human V2 receptor expressed in CHO cells		B
748964	Displacement of [3H]SCH233930 from human D1 receptor expressed in HEK cells		B
751198	Inhibition of human recombinant NTS1 receptor at 10 uM by radioligand binding assay		B
758945	Antibacterial activity against Escherichia coli ATCC 8739 at 2 mg/ml after 24 hrs by agar-well diffusion technique	agar-well diffusion technique	F
764674	Displacement of [3H]Iloprost from human prostanoid IP receptor expressed in CHO cells after 60 mins by liquid scintillation counting	liquid scintillation counting	B
770814	Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay	SRB assay	F
774208	Binding constant for NIM1 kinase domain		B
774448	Binding constant for DRAK1 kinase domain		B
775804	Displacement of [3H]-epibatidine from alpha1betagammadelta nAChR in human TE671 cellular membranes at 5 uM after 2 hrs by liquid scintillation counting	liquid scintillation counting	B
788137	Inhibition of human recombinant RON at 0.5 uM by radiometric filter-binding assay	radiometric filter-binding assay	B
790543	Inhibition of basal activity of human histamine H3 receptor expressed in CHO cells assessed as inhibition of RAHM-induced [35S]GTPgammaS binding after 4 hrs by beta liquid scintillation counting	beta liquid scintillation counting	F
790861	Antibacterial activity against erythromycin-sensitive Staphylococcus aureus ATCC 13709 by broth microdilution method	broth microdilution method	F
793560	Displacement of [3H]-PGE2 from mouse EP4 receptor expressed in CHO cells after 60 mins by liquid scintillation counter	liquid scintillation counter	B
795125	Antibacterial activity against Bacillus at 10 mg/ml after 24 hrs by cut-plug method	cut-plug method	F
795795	Displacement of [3H]histamine from rat H1R		B
795958	Inhibition of human recombinant MMP12-induced lung inflammation in C57BL/6 mouse assessed as reduction in bronchoalveolar lavage inflammation at 5 mg/kg, po bid at 2 hrs prior to and 12 hrs post challenge measured 24 hrs after last challenge relative to vehicle treated control		F
796334	Cell cycle arrest in human SK-BR-3 cells assessed as accumulation at G2/M phase at 0.25 uM after 18 hrs using propidium iodide staining by FACS analysis	propidium iodide staining by FACS analysis	F
798461	Binding affinity to N-terminus biotinylated human Hsp90 alpha by surface plasmon resonance assay	surface plasmon resonance assay	B
801636	Antifungal activity against Penicillium funiculosum ATCC 36839 treated for 72 hrs followed by sub-cultivated for 5 days by serial dilution method	serial dilution method	F
802309	Binding affinity at 5-HT2A receptor by radioligand displacement assay		B
809816	Antioxidant activity using deaerated 1 M ethylene glycol as substrate assessed as hydroxy radical additive level at 1 mmol/L after gamma-irradiation		F
811334	Inhibition of N-terminal 6-histine tagged Bacillus anthracis LF 263-C terminal catalytic domain using MCA-KKVYPYPME-Dap(Dnp)-NH2 as substrate after 4 hrs by FRET analysis	FRET analysis	B
812850	Inhibition of PI3K p110alpha E545K mutant using [gamma33P]ATP by filter binding assay	filter binding assay	B
815840	Binding affinity to calf thymus DNA assessed as melting temperature		B
815855	Inhibition of GPIbalpha-vWF binding assessed as inhibition of ristocetin-induced platelet agglutination at 100 uM after 2 mins by static agglutination assay	static agglutination assay	B
818809	Binding affinity to human recombinant 5HT2C receptor		B
819365	Antibacterial activity against Bacillus subtilis ATCC 6633 assessed as partial clear inhibition zone at 50 uL of 2 mM solution of compound in 1:9 DMSO/MeOH after 24 hrs by agar diffusion method	agar diffusion method	F
820687	Antidyslipidemic activity in fasted beagle dog assessed as reduction in free fatty acid level in plasma at 2 mg/kg, po after 1 hr relative to vehicle-treated control		F
820807	Agonist activity at human S1P3 receptor expressed in CHO cells coexpressing Gq/i5 G-protein assessed as Ca2+ mobilization after 60 to 90 mins by FLIPR assay relative to 1-(4-(6-benzylbenzofuran-2-yl)-3-fluorobenzyl)azetidine-3-carboxylic acid	FLIPR assay	F
825615	Growth inhibition of human CCRF-CEM cells assessed as cell growth at 10'-5 M after 48 hrs by SRB assay	SRB assay	F
830179	Antimigraine activity in marmosets assessed as inhibition of CGRP-induced increase in facial blood flow at 1 mg/kg, sc administered 30 mins post CGRP-challenge measured up to 105 mins by laser doppler flowmetry	laser doppler flowmetry	F
833701	Antitumor activity against human A549 cells xenografted in nu/nu mouse assessed as inhibition of tumor volume at 3 mg/kg, ip administered three times a week for 3 weeks		F
834505	Anticonvulsant activity in mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip after 4 hrs		F
834886	Antioxidant activity assessed as inhibition of DPPH radical at 1 to 20 mM after 15 mins		F
835167	Inhibition of FGFR2 by TR-FRET analysis	TR-FRET analysis	B
839971	Inhibition of PI3K alpha by continuous TR-FRET assay	continuous TR-FRET assay	B
841245	Antibacterial activity against Listeria innocua after 24 hrs by microtitre plate reader		F
848248	Antifungal activity against Aspergillus fumigatus ATCC 26934 by NCCLS broth microdilution method	NCCLS broth microdilution method	F
852592	Displacement of [3H]CCPA from adenosine A1 receptor in rat brain cortical membrane		B
855142	Fungicidal activity against Trichoderma viride CECT 2423 at 0.2 mg/disk after 48 hrs by agar diffusion assay	agar diffusion assay	F
855538	Displacement of [3H]-5-CT from human 5-HT7b receptor expressed in HEK293 cells after 1 hr		B
857664	Growth inhibition of human MDA-MB-231 cells after 72 hrs by celltiter-blue viability assay	celltiter-blue viability assay	F
857710	Antiobesity activity in po dosed wild type DIO C57 mouse assessed as reduction of food intake		F
860849	Displacement of [3H]epibatidine from rat alpha2beta4 nACHR at 10 uM		B
876212	Inhibition of radioligand binding to human adrenergic alpha2c receptor at 10 uM		B
876226	Agonist activity at rat mGlu8R expressed in HEK293 cells co-expressing GIRK channels by thallium flux assay	thallium flux assay	F
877015	Binding affinity to mGlu1 receptor in rat brain pons at 7.4 MBq after 60 mins by autoradiography	autoradiography	B
877019	Binding affinity to mGlu1 receptor in rat thalamus at 7.4 MBq after 60 mins by autoradiography	autoradiography	B
877041	Inhibition of mTORC1 in human PC3 cells xenografted mouse assessed as reduction of phosphorylated p70S6K level at 25 to 100 mg/kg, po after 6 hrs		F
877387	Transactivation of GAL4-fused human PPARdelta ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay	luciferase reporter gene assay	B
887349	Binding affinity to human cyclophilin A by fluorescence polarization assay	fluorescence polarization assay	B
892427	Antifungal activity against Rhizoctonia solani assessed as inhibition of mycelium growth after 2 days		F
894707	Induction of ultrastructure damage of root tip statocytes in Zea mays (maize) seedlings assessed as reduction in organelle size at 400 ug/L measured 48 hr post dose by transmission electron microscopy	transmission electron microscopy	F
902639	Antihyperlipidemic activity in high fat-high cholesterol fed New Zealand Oryctolagus cuniculus (rabbit) assessed as total cholesterol level in blood at 10 mg/kg, po for 40 days (Rvb = 8.74 +/- 0.53 mmol/l)		F
909420	Anticoagulant activity in Rattus norvegicus Wistar (rat) diabetic-hyperlipidemic model assessed as decrease in TFa activity in aorta measuring clotting time at 10.91% administered through feeding measured after 12 weeks (Rvb = 36.25 +/- 1.39 secs)		F
912047	Hypolipidemic activity in high cholesterol diet fed Mus musculus KM (mouse) assessed as low density lipoprotein cholesterol at 150 mg/kg, ig for 10 days (Rvb = 4.2972 +/- 1.1725 mmol/l)		F
912430	Antidiabetic activity against STZ-induced diabetic Rattus norvegicus Wistar albino (rat) assessed as change in hemoglobin at 20 mg/kg, po administered via intragastric tube for 45 days (Rvb = 8.5 +/-0.9 mg/dl)		F
916663	Antifungal activity against Rhizoctonia solani SRRC 1443 assessed as thin hyphae at 20 uM after 48 hr by microscopic analysis	microscopic analysis	F
919254	Antiviral activity against Tobacco mosaic virus (TMV) inoculated in whole leaves of Nicotiana tabacum L. assessed as curative effect measured as local lesion number at 50 mg/l after 3 to 4 days		F
923116	Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as diameter of growth inhibition zone at 100 ug/ml after 24 hr by cup-plate method	cup-plate method	F
924368	Herbicidal activity against Monochoria vaginalis assessed as weed control in transplanted rice field at 30 g/ha treated after 15 days transplanting		F
926118	Antifungal activity against sithiofam-sensitive Gaeumannomyces graminis var. tritici isolate HN21 expressing C2 genetic cluster assessed as reduction in fungal colony diameter after 4 days		F
926224	Inhibition of Nitrosomonas europaea ATCC 25978-mediated nitrification activity assessed as nitrite nitrogen formation at 0.5 mg/kg after 7 to 10 days by Griess-Ilosvay method relative to control	Griess-Ilosvay method	F
926445	Decrease in Botryosphaeria dothidea ligninolytic enzyme production assessed as laccase activity using ABTS as substrate at 25 mM measured at 28 degC after 4 days		F
936279	Bactericidal activity against Salmonella typhi after 72 hrs by serial subcultivation method	serial subcultivation method	F
938376	Displacement of [3H]WIN-55,212-2 from human recombinant CB2 receptor expressed in CHO-K1 cells at 10 uM relative to control		B
939587	Antimalarial activity against chloroquine, mefloquine and halofantrine-resistant Plasmodium yoelii nigeriensis infected in Swiss mouse assessed as protection against parasite-induced mortality at 24 mg/kg, po administered for 4 days measured on day 28		F
941525	Ratio of TXA IC50 to compound IC50 for human Glu-plasminogen/fibrinogen interaction by clot-lysis buffer assay	clot-lysis buffer assay	B
944109	Binding affinity to JAK1 (unknown origin) at 10 uM relative to control		B
945494	Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay	sulforhodamine B assay	F
948159	Antibacterial activity against methicillin-susceptible, MLS-resistant (inducible) Staphylococcus epidermidis E1 by broth microdilution method	broth microdilution method	F
953228	Cytotoxicity against human A549/ATCC cells after 48 hrs by SRB assay	SRB assay	F
963022	Binding affinity to 5HT2A receptor (unknown origin)		B
963174	Binding affinity to human dopamine D1 receptor by radioligand binding assay		B
964025	Cell cycle arrest in human Bel7402 cells assessed as accumulation at S phase at 0.15 uM after 48 hrs by propidium iodide staining-based FACS analysis (Rvb = 39.17 %)	propidium iodide staining-based FACS analysis	F
964384	Binding affinity to human MC4 receptor at 10 uM by radioligand displacement assay relative to control		B
965434	Displacement of [3H]8-OH-DPAT from human recombinant 5HT1A receptor expressed in CHOK1 cells after 60 mins		B
966209	Binding affinity to human adenosine A1 receptor by radioligand displacement assay		B
966269	Cell cycle arrest in human MGC803 cells assessed as reduction in G1 phase accumulation after 12 to 24 hrs by propidium iodide staining-based flow cytometry	propidium iodide staining-based flow cytometry	F
969677	Displacement of [3H]Citalopram from SERT in Sprague-Dawley rat brain homogenate after 60 mins by scintillation counting analysis	scintillation counting analysis	B
976258	Antioxidant activity assessed as DPPH radical scavenging activity at 40 uM after 30 mins		F
976681	Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cells up to 0.1 mM after 2 hrs by scintillation counting analysis	scintillation counting analysis	B
978205	Trypanocidal activity against epimastigote stage of Trypanosoma cruzi Y at 5 ug/mL after 72 hrs by MTT assay relative to control	MTT assay	F
981821	Binding affinity to PPARgamma (unknown origin) at 10 uM by Polarscreen competitor assay relative to rosiglitazone	Polarscreen competitor assay	B
983824	Antifungal activity against Saccharomyces cerevisiae MTCC 36 at 50 ug/ml after 48 hrs by agar well diffusion method	agar well diffusion method	F
985206	Inhibition of His-thrombin-TEV-tagged cIAP1 BIR3 domain (260 to 352) (unknown origin) after 1 hr by TR-FRET assay	TR-FRET assay	B
987775	Growth inhibition of human NCI-ADR-RES cells assessed as cell growth at 10'-5 M after 48 hrs by sulforhodamine B assay relative to control	sulforhodamine B assay	F
989337	Antiproliferative activity against human HCT8 cells by MTT assay	MTT assay	F
989636	Binding affinity to N-terminal domain of human Hsp90alpha by FAXS competitive binding assay	FAXS competitive binding assay	B
990003	Trypanocidal activity against bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a after 72 hrs by AlamarBlue assay	AlamarBlue assay	F
990753	Displacement of [3H]N-alpha-methylhistamine from rhesus monkey histamine H3 receptor expressed in CHO cells		B
991378	Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mouse assessed as reduction of parasitemia at 10 mg/kg, po qd administered 3 days by flow cytometric analysis	flow cytometric analysis	F
1275686	Inhibition of LYN (unknown origin) after 90 mins by TR-FRET/IMAP fluorescence polarization assay	TR-FRET/IMAP fluorescence polarization assay	B
1277119	Binding affinity to human recombinant TLR4 at >320 uM by SPR method	SPR method	B
1278477	Binding affinity to human 5-HT3A receptor W90C mutant after 24 hrs by liquid scintillation counting analysis	liquid scintillation counting analysis	B
1279931	Binding affinity to AT1 receptor (unknown origin)		B
1283562	Antiinflammatory activity in human THP1 cells assessed as inhibition of TPA/ionomycin-induced extracellular IL-1beta level at 3 uM incubated 1 hr prior to TPA/ionomycin challenge measured after 24 hrs by ELISA	ELISA	F
1284858	Growth inhibition of human OVCAR8 cells after 48 hrs by sulforhodamine B assay	sulforhodamine B assay	F
1285619	Displacement of [125I]Sarile from human AT2 receptor expressed in HEK293 cells		B
1291412	Growth inhibition of Saccharomyces cerevisiae BY4742 harboring gcn5delta mutant after 48 hrs		F
1329184	Displacement of [3H]-pentazocine from human recombinant sigma-1 receptor expressed in CHO cells after 180 mins by beta counting analysis	beta counting analysis	B
1329392	Binding affinity to NR4A1 (unknown origin) at 0.1 uM by luciferase reporter gene assay relative to control	luciferase reporter gene assay	B
1329505	Competitive binding affinity to GLO-1 in HEK293T cell lysate at 50 uM after overnight incubation followed by UV-irradiation for 1 hr by pull-down assay in presence of N-(4-(4-(5-fluoro-4-(2-(methylsulfonamido)phenylamino)pyrimidin-2-ylamino)benzoyl)phenyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide	pull-down assay	B
1329746	Binding affinity to M4 receptor (unknown origin) by PDSP assay		B
1330988	Growth inhibition of human MDA-MB-231 cells assessed as cell growth at 10'-5 M after 48 hrs by sulforhodamine B assay	sulforhodamine B assay	F
1331128	Growth inhibition of human MDA-MB cells		F
1334710	Growth inhibition of human NCI-H226 cells		F
1335988	Antihypertensive activity in Wistar rat assessed as mean arterial pressure at 10 mg/kg, ip measured immediately at 0 min (Rvb = 194.08 +/- 1.962 mmHg)		F
1337555	Neuroprotective activity in glutamate-induced mouse HT22 cells assessed as decrease in ROS level at 1 uM after 12 hrs by H2DCF diacetate-based flow cytometric analysis	H2DCF diacetate-based flow cytometric analysis	F
1338888	Antitumor activity against mouse S180 cells allografted in ddY mouse assessed as tumor growth inhibition at 10 mg/kg, po administered once every 2 days for 2 weeks relative to control		F
1339546	Induction of apoptosis in human A549 cells assessed as necrotic cells at 5 uM after 48 hrs by annexin V/PI staining-based FACS analysis (Rvb = 2.8 %)	annexin V/PI staining-based FACS analysis	F
1349583	Induction of apoptosis in p53 knock down human HCT116 cells assessed as PARP cleavage at 1 uM after 24 hrs by immunoblotting analysis	immunoblotting analysis	F
1356171	Hypolipidemic activity in Wistar rat assessed as reduction in plasma cholesterol level at 499 umol/kg/day administered through diet for 4 days		F
1368390	Relative resistance, ratio of IC50 for human SKOV3 cells expressing MDR1/M-6-6 to IC50 for human SKOV3 cells		F
1432679	Inhibition of integrin alphavbeta3 (unknown origin) by Merck binding assay		B
1438531	Antibacterial activity against erythromycin-susceptible Staphylococcus aureus by agar microdilution method	agar microdilution method	F
1455786	Stimulation of growth in human MCF7 cells at 0.1 to 20 uM after 4 days by MTT assay	MTT assay	F
1457920	Inhibition of human 5HT3 at 10 uM by [3H]RL43694 binding assay relative to control		B
1460139	Displacement of [3H]spiperone from human D4.4 receptor stably expressed in CHO cell membranes by competitive binding assay		B
1460861	Ratio of Kd for GST-tagged phosphorylated p38-alpha (unknown origin) to IC50 for uman recombinant 5'-c-myc, His6-tagged p38-alpha using MK2 (46-400) as substrate		B
1461117	Antimicrobial activity against Bacillus subtilis ATCC 6633 assessed as inhibition of microbial growth incubated for 24 hrs by broth dilution method	broth dilution method	F
1461457	Cytotoxicity against human A673 cells after 96 hrs by MTS assay	MTS assay	F
1462240	Cell cycle arrest in human MCF7 cells assessed as accumulation at G0 phase at 2 uM after 48 hrs by FACS analysis (Rvb = 1.83 +/- 0.28%)	FACS analysis	F
1463128	Intrinsic activity at GAL4 tagged human PPARalpha ligand binding domain expressed in HEK293 cells at 1 uM by luciferase reporter gene assay relative to 1 uM GW2331	luciferase reporter gene assay	B
1464501	Displacement of S6c from rat ETB receptor after 1 hr by Lowry method	Lowry method	B
1472216	Induction of apoptosis in human HepG2 cells assessed as viable cells at 20 uM after 6 hrs by annexin V/propidium iodide staining-based flow cytometric analysis (Rvb = 90.9%)	annexin V/propidium iodide staining-based flow cytometric analysis	F
1475233	Binding affinity to RPA70N protein (unknown origin) by HSQC NMR-based titration method	HSQC NMR-based titration method	B
1475850	Antimycobacterial activity against Mycobacterium sp.		F
1477470	Antimicrobial activity against Bacillus subtilis ATCC 6633 after 24 hrs by twofold dilution method	twofold dilution method	F
1478223	Antiviral activity against Hepatitis C virus genotype 1b Con 1 infected in human HuH7 cells at 40 nM after 72 hrs by luciferase assay in presence of 24 nM simeprevir	luciferase assay	F
1500556	Binding affinity to FLAG-6His-Tev-ATAD2 (950 to 1148) Y1021A/N1064A double mutant (unknown origin) expressed in Escherichia coli BL21 (DE3) by SPR analysis	SPR analysis	B
1502837	Binding affinity to KAT2A in human HUT78 cells incubated for 45 mins by mass spectrometry based bromosphere chemoproteomic assay	mass spectrometry based bromosphere chemoproteomic assay	B
1513272	Antitumor activity against human NCI-H3122 cells xenografted in SCID mouse assessed as tumor growth inhibition at 50 mg/kg, po qd for 14 days		F
1514952	Displacement of [3H]raclopride from dopamine D2 receptor in Sprague-Dawley rat striatal membranes after 30 mins		B
1516953	Induction of apoptosis in human MGC803 cells assessed as compact and condensed chromatin at 10 uM after 48 hrs using Hoechst 33258 staining by fluorescence microscopic analysis	Hoechst 33258 staining by fluorescence microscopic analysis	F
1521285	Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 expressing luciferase reporter gene infected in mouse J-774A1 cells assessed as inhibition of amastigote stage formation incubated for 72 hrs by luminometry	luminometry	F
1525254	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 18 to 24 hrs by spectrophotometric analysis	spectrophotometric analysis	F
1525752	Agonist activity at dopamine D4 receptor (unknown origin) expressed in CHO cells assessed as calcium mobilization at 3 uM		F
1539358	Effect on LKB1 expression in mouse 3T3L1 cells at 0.2 mM after 10 mins, 2 and 24 hrs by western blot analysis	western blot analysis	F
1543802	Anticonvulsant activity in CF1 albino mouse assessed as protection against 6 Hz-psychomotor-induced seizure at 50 mg/kg, ip after 4 hrs		F
1544235	Inhibition of Rsk3 (unknown origin) at 1 uM		B
1545083	Displacement of [3H]-ketanserin from human 5-HT2A receptor expressed in HEK293 cells incubated for 1 hr		B
1545991	Antiangiogenic activity in po dosed Brown Norway rat laser-induced choroidal neovascularization model assessed as inhibition of neovascular lesion formation administered qd for 14 days by microscopic analysis	microscopic analysis	F
1546446	Inhibition of human c-Kit using poly[Glu:Tyr] (4:1) as substrate		B
1547676	Inhibition of human recombinant MMP10 expressed in Escherichia coli using (5-FAM/QXLTM) FRET peptide as substrate		B
1551515	Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay	Caliper motility shift assay	B
1554559	Binding affinity to recombinant 5-HT1B receptor (unknown origin) after 1.5 hrs by radioligand displacement assay		B
1555070	Displacement of 5-(Dimethylamino)-2-(6-((5-(4-(4-methylpiperidin-1-yl)butyl)-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)hexyl)isoindoline-1,3-dione from sigma 1 receptor (unknown origin) expressed in MCF7 after 75 mins by flow cytometry	flow cytometry	B
1558050	Inhibition of BRPF3 (unknown origin) by Alpha Screen assay	Alpha Screen assay	B
1558657	Inhibition of human recombinant NQO2 using DCPIPas substrate and NRH as cofactor measured for 1 min by spectrophotometry in the absence of BSA	spectrophotometry	B
1559495	Displacement of [125I]Endothelin-1 from human recombinant Endothelin-B receptor expressed in CHO cells at 10'-5 M		B
1561733	Induction of apoptosis in human K562 cells assessed as downregulation of Bcl-2 protein expression by Western blot analysis	Western blot analysis	F
1561734	Induction of apoptosis in human K562 cells assessed as up-regulation of Bax protein expression by Western blot analysis	Western blot analysis	F
1562687	Inhibition of N-terminal His6-tagged recombinant human HCK expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control		B
1564255	Antibacterial activity against Pseudomonas aeruginosa PAO1 clinical isolate assessed as inhibition of biofilm formation at 4 ug/ml after 18 to 22 hrs by crystal violet staining-based polystyrene microtiter plate reader method in presence of 0.5 ug/ml colistin	crystal violet staining-based polystyrene microtiter plate reader method	F
1565155	Displacement of [3H]CP55940 from CB1 receptor in Wistar rat brain incubated for 60 mins by radioactive filter binding assay	radioactive filter binding assay	B
1565356	Inhibition of human recombinant PTP-1B using IR5 insulin receptor residues as substrate at 100 uM after 30 mins by malachite green assay	malachite green assay	B
1565425	Inhibition of human His-tagged BRD4 bromodomain 2 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by FRET assay	FRET assay	B
1568614	Agonist activity at rat mGlu2 receptor by FRET based mGlu sensor assay	FRET based mGlu sensor assay	B
1571983	Inhibition of HDAC9 catalytic domain (unknown origin) using Boc-Lys(TFA)-AMC as substrate		B
1575333	Inhibition of GARFTase (unknown origin)		B
1576400	Binding affinity to HIV1 protease N88D mutant		B
1576452	Inhibition of PRMT6 (unknown origin) at 10 uM relative to control		B
1578804	Inhibition of human ROCK2 (1 to 431 amino acid residues) assessed as enzyme activity at 10 uM by KINOMEScan assay	KINOMEScan assay	B
1578808	Inhibition of human SRPK3 (41 to 567 amino acid residues) expressed in bacterial system assessed as enzyme activity at 10 uM by KINOMEScan assay	KINOMEScan assay	B
1580193	Potentiation of 2.5 nM (-)-lomaiviticin A-induced cytotoxicity against human K562 cells assessed as combination index at 10 uM after 48 hrs by cell titer-glo luminescence assay	cell titer-glo luminescence assay	F
1582085	Displacement of biotinylated ligand from recombinant His-tagged EP300 (unknown origin) incubated for 10 mins by TR-FRET assay	TR-FRET assay	B
1582930	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay	MTT assay	F
1583101	Inhibition of full length recombinant human GST-tagged PRKX expressed in baculovirus expression system at 1 uM relative to control		B
1583673	Inhibition of PI3K delta (unknown origin)		B
1585034	Binding affinity to MDM2 in human U87MG cells assessed as inhibition of MDM2/p53 protein interaction after 10 mins by quantitative sandwich immuno assay	quantitative sandwich immuno assay	B
1587012	Inhibition of CDK8 (unknown origin)		B
1588202	Binding affinity to His6-tagged human recombinant SMARCA2B bromodomain expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by VP-ITC microcalorimetry	VP-ITC microcalorimetry	B
1589315	Cytotoxicity against human KB cells assessed as reduction in cell viability at >50 ug/ml by resazurin microplate assay	resazurin microplate assay	F
1613700	Inhibition of activated protein C (unknown origin) at 37 degC by chromogenic substrate assay	chromogenic substrate assay	B
1615230	Effect on ITGB2 gene expression in serum-starved HUVEC after 6 hrs by microarray analysis relative to control	microarray analysis	F
1615232	Effect on KIF11 gene expression in serum-starved HUVEC after 6 hrs by microarray analysis relative to control	microarray analysis	F
1621810	Inhibition of OGT (unknown origin) assessed as reduction in GlcNAc transfer to CKII peptide at 100 uM incubated for 60 mins by HPLC method	HPLC method	B
1625341	Inhibition of human ABCB1 expressed in KBV1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 5.07 +/- 0.19 uM)	MTT assay	B
1629935	Reversible inhibition of recombinant human C-terminal His6-tagged IDO2 (14-420 residues) expressed in Escherichia coli BL21(DE3) assessed as reduction in L-kynurenine formation using L-tryptophan as substrate after 30 mins		B
1630356	Bactericidal activity against Mycobacterium smegmatis MC2 155 assessed as log reduction in bacterial colonies at 4 times MIC measured after 24 hrs by time-kill assay		F
1632014	Binding affinity to rat M2 receptor by radio-ligand binding assay		B
1634426	Stabilization of BRAF in human K562 cells after 1 hr by thermal shift assay	thermal shift assay	B
1636438	Potency index, ratio of galantamine IC50 to compound IC50 for horse serum BuChE		B
1644719	Binding affinity to full length recombinant human N-terminal His8-tagged Cyclophilin A (1 to 169 residues) expressed in Escherichia coli BL21(DE3) assessed as change in entropy at 225 to 300 uM by ITC	ITC	B
1645352	Analgesic activity in CFA-induced mechanical hyperalgesia C57BL/6J mouse model assessed as mechanical paw withdrawal threshold at 3 ug/10 uL administered intrathecally 2 days after CFA injection measured at 90 to 150 mins post dose		F
1646002	Inhibition of human RIPK1 (M1 to K305 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by KINOMEscan assay relative to control	KINOMEscan assay	B
1647301	Growth inhibition of human HCC2998 cells assessed as cell growth at 5 uM incubated for 48 hrs by sulforhodamine B assay relative to control	sulforhodamine B assay	F
1647420	Growth inhibition of human KM12 cells assessed as cell growth at 0.003 uM incubated for 48 hrs by sulforhodamine B assay relative to control	sulforhodamine B assay	F
1648344	Inhibition of PTP1B in human HuH7 cells assessed as reduction in insulin-stimulated Akt phosphorylation at 5 uM preincubated for 2 hrs followed by insulin stimulation for 5 mins by Western blot method	Western blot method	B
1650979	Displacement of [3H]NVP-QAW039 from human DP2 receptor expressed in CHO cell membranes assessed as association rate constant by TopCount scintillation assay	TopCount scintillation assay	B
1651596	Antitumor activity against mouse H22 cells implanted in Kunming mouse assessed as tumor growth inhibition at 24 mg/kg, ip administered once in every 3 days totally for 3 times relative to control		F
1651980	Poison activity at recombinant human topoisomerase-2alpha expressed in Saccharomyces cerevisiae JEL1 harboring topoisomerase1 deletion mutant assessed as increase in double stranded DNA cleavage at 1 mM using supercoiled pBR322 DNA as substrate preincubated for 1 to 5 mins followed by substrate addition measured after 6 mins by ethidium bromide staining based agarose gel electrophoresis	ethidium bromide staining based agarose gel electrophoresis	B
1652717	Inhibition of ATP citrate lyase in snail expressing HMLE cells assessed as suppression of cancer stemness by measuring CD44 positive/negative and CD24 positive cells at 10 uM after 48 hrs by flow cytometry (Rvb = 4.85 %)	flow cytometry	B
1656536	Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay	sulforhodamine B assay	F
1658550	Binding affinity to PPARgamma (unknown origin) assessed as kinetic dissociation constant by SPR assay	SPR assay	B
1659245	Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as parasite cure level at 10 to 90 mg/kg, ip administered on days 1 post infection by Giemsa-stained microscopic analysis	Giemsa-stained microscopic analysis	F
1659301	Binding affinity to DYRK1A in human U251 cell lysate preincubated for 1 hr followed by incubation at 54 degreeC for 3 mins by isothermal dose-response fingerprint assay	isothermal dose-response fingerprint assay	B
1659644	Inhibition of LTB4 biosynthesis in LPS-induced C57BL/6 mouse model of acute lung injury BLAF at 25 mg/kg, ip by ELISA	ELISA	F
1660709	Inhibition of TLR9 in human PBMC assessed as reduction in ODN2216-stimulated IFNalpha expression at 1 to 10 uM by ELISA	ELISA	B
1661450	Inhibition of TNFalpha-stimulated RIPK2 in human U937 cells in presence of 5 uM ATP		B
1667363	Potentiation of 0.316 uM cisplatin-induced cytotoxicity against human CAL27 cells assessed as decrease in cell viability by measuring combination index at 900 uM preincubated for 48 hrs followed by cisplatin treatment measured after 72 hrs by MTT assay	MTT assay	F
1670804	Binding affinity to recombinant human GFP-fused ERalpha LBD (301 to 553 residues) expressed in Escherichia coli BL21(DE3) in presence of 17beta-estradiol by ITC	ITC	B
1671992	Cytotoxicity against human MCF7 cells by MTT assay	MTT assay	F
1672555	Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method	filter binding method	B
1673543	Displacement of [3H]-CP55950 from human CB1 receptor expressed in CHO cell membranes after 3 hrs by scintillation counting method	scintillation counting method	B
1673874	Displacement of [125I]-[Nle75, Tyr77] Pyr1-apelin-13 from YFP-tagged human APJ receptor expressed in HEK293 cell membranes after 1 hr by gamma-counting method	gamma-counting method	B
1674489	Agonist activity at human NOD2 expressed in HEK-Blue cells assessed as induction of NF-kB transcriptional activity at 20 uM after 18 hrs by SEAP reporter gene assay	SEAP reporter gene assay	B
1674696	Ratio of Kinact to Ki for S-adenosyl-L-homocysteine hydrolase (unknown origin)		B
1674858	Inhibition of wild-type human ACVR2A (V171 to T499 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1675304	Inhibition of wild-type human partial length YSK4 (T1019 to H1328 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1676262	Inhibition of human PDE4D catalytic domain using [3H]-cAMP as substrate after 30 mins by scintillation counting method	scintillation counting method	B
1679271	Binding affinity to partial length human HIPK1 (M146 to I555 residues) expressed in mammalian expression system assessed as unbound drug level at 300 nM by KINOMEscan assay	KINOMEscan assay	B
1679715	Antibacterial activity against Bacillus subtilis NBRC 13719 after overnight incubation by microdilution method	microdilution method	F
1681112	Inhibition of human FLT3 K663Q mutant (V592 to Y969 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan assay relative to control	Kinomescan assay	B
1683894	Inhibition of MAP2K3 Lysine 2 labelling site (unknown origin) at 10 uM		B
1690980	Antibacterial activity against Escherichia coli MTCC 443 after 24 hrs by broth microdilution method	broth microdilution method	F
1691198	Inhibition of human GSK3beta using YRRAAVPPSPSLSRHSSPHQS(PO4)EDEEENH as substrate after 60 mins in presence of [gamma32P]ATP by TopCount method	TopCount method	B
1691517	Inhibition of chymotrypsin-like activity of 20S proteasome in human HL60 cells using Suc-LLVYaminoluciferin as substrate at 2 uM after 2 hrs by fluorescence analysis	fluorescence analysis	B
1692148	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 4 hrs by MTT assay	MTT assay	F
1692973	Inhibition of wild-type human full length CDK3 (M1 to H305 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	Kinomescan method	B
1693188	Inhibition of wild-type human partial length NDR2 (N34 to E447 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	Kinomescan method	B
1696265	Inhibition of mTOR binding to DEPTOR in human RPMI8226 cells assessed as increase in mTORC1-associated p70 phosphorylation after 6 hrs by Western blot analysis relative to control	Western blot analysis	B
1698355	Displacement of [125I]SDF-1alpha from CXCR4 (unknown origin) expressed in HEK293 cells after 1 hr by scintillation counting method	scintillation counting method	B
1698440	Antagonist activity at muscarinic M1 receptor (unknown origin)		B
1699332	Inhibition of human MSK1 assessed as residual activity at 1 uM in presence of 33P-ATP by filter-binding assay relative to control	filter-binding assay	B
1701466	Binding affinity to human N-terminal MDMx (1 to 134 residues) expressed in Escherichia coli BL21 (DE3) after 15 mins in presence of 5-FAM-LTFEHYWAQLTS by FP assay	FP assay	B
1701883	Increase in OPG mRNA expression in mouse MC3T3-E1 cells up to 4 uM after 48 hrs in presence of ascorbic acid and beta-glycerophosphate by real-time PCR analysis	real-time PCR analysis	F
1703545	Displacement of [3H]spiperone from human D2-short receptor expressed in CHO cell membranes		B
1703701	Inhibition of wild-type human partial length PKCH (S324 to P683 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	Kinomescan method	B
1704689	Inhibition of human recombinant MMP-9 catalytic domain (107 to 449 residues) expressed in Escherichia coli using fluorogenic MOCAc-Pro-Leu-Gly-Leu-A2pr(Dnp)-Ala-Arg-NH2 as substrate at 10 uM by fluorescence spectrophotometric analysis	fluorescence spectrophotometric analysis	B
1706120	Inhibition of NuaK1 (unknown origin) at 0.45 uM relative to control		B
1707368	Displacement of biotinylated histone H3K14 peptide ligand from human recombinant His-tagged BRD4 bromodomain-1 measured after 10 mins by TR-FRET assay	TR-FRET assay	B
1707818	Inhibition of HuR-ERBB2 mRNA interaction in human MCF7 cells at 5 uM after 6 hrs by RNA immunoprecipitation assay	RNA immunoprecipitation assay	B
1708265	Inhibition of CaMK2g in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled TSTQEYAAKIINTK probe by mass-spectrometric analysis relative to control	mass-spectrometric analysis	B
1708497	Binding affinity to YWHAQ in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	mass spectrometry based pull down assay	B
1708761	Binding affinity to HAX1 in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay	mass spectrometry based pull down assay	B
1708876	Binding affinity to AURKB in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay	mass spectrometry based pull down assay	B
1708895	Binding affinity to MAP2K2 in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay	mass spectrometry based pull down assay	B
1710591	Inhibition of DYRK3 (unknown origin) at 0.19 uM relative to control		B
1711349	Displacement of [3H]BRL 43694 from human recombinant 5-HT3 receptor at 10 uM after 120 mins by scintillation counting analysis relative to control	scintillation counting analysis	B
1711487	Inhibition of recombinant His-tagged human FGFR1 cytoplasmic domain expressed in baculovirus expression system at 10 uM in presence of ATP relative to control		B
1717246	Induction of apoptosis in human MGC803 cells assessed as late apoptotic cells at 8 uM after 48 hrs Annexin V-FITC/propidium iodide based flow cytometry (1%)	Annexin V-FITC/propidium iodide based flow cytometry	F
1717988	Activation of ABCG2 ATPase activity (unknown origin) expressed in baculovirus infected high5 cell membranes assessed as enzyme activity at 56 nM after 20 mins by ascorbic acid ammonia molybdate reaction based colorimetric assay relative to control	colorimetric assay	B
1718296	Inhibition of AKT (unknown origin) assessed as residual activity at 10 uM relative to control		B
1721442	Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay	MTT assay	F
1724006	Inhibition of human SMS2 expressed in HEK293T cells at 100 uM using C2-ceramide as substrate preincubated for 60 mins followed by substrate addition measured after 30 mins by RapidFire/mass spectrometry assay relative to control	RapidFire/mass spectrometry assay	B
1724104	Displacement of [3H]muscimol from human GABAA receptor alpha1beta3gamma2 expressed in HEK293 TetR cell membranes after 1 hr by liquid scintillation counting method	liquid scintillation counting method	B
1724121	Binding affinity to human GABAA receptor alpha1beta3gamma2 expressed in HEK293 TetR cells assessed as photolabeling at 0.7 uM after 30 mins in presence of 300 uM GABA by coomassie blue staining based fluorographic method	coomassie blue staining based fluorographic method	B
1724375	Antiproliferative activity against human LNCAP cells after 48 hrs by CCK-8 assay	CCK-8 assay	F
1727619	Induction of apoptosis in human HCC827 cells assessed as increase in hypodiploid DNA content at 50 to 100 nM after 72 hrs by propidium iodide staining flow cytometry	propidium iodide staining flow cytometry	F
1729642	Inhibition of recombinant human DGAT1 expressed in baculovirus infected Sf9 insect microsomal membranes using C10-DAG and [3H]-labelled decanoyl-CoA as substrates pretreated for 30 mins in presence of C10-DAG followed by [3H]-labelled decanoyl-CoA addition measured after 60 mins by microbeta counting method	microbeta counting method	B
1729907	Inhibition of recombinant human JAK3 (781 to 1124 residues) expressed in insect cells using 5FAM-GEEPLYWSFPAKKK-NH2 as substrate after 10 mins by caliper assay	caliper assay	B
1730073	Inhibition of GAK in human HuH7 cells assessed as reduction in AP2M1 phosphorylation levels up to 10 uM after 4 hrs in presence of PP2A inhibitor calyculin A by Western blot analysis	Western blot analysis	B
1730151	Antagonist activity at CCR10 in human MDA-MB-231 cells assessed as inhibition of CCL27-induced proliferation up to 10 uM preincubated for 2 hrs followed by CCL27 addition measured after 48 hrs by MTT assay	MTT assay	F
1731240	Antifungal activity against Candida albicans ATCC 90028 assessed as inhibition of metabolic activity at 10 ug/ml after 48 hrs in presence of 80 ug/ml fluconazol by XTT assay relative to control	XTT assay	F
1734342	Negative allosteric modulation of human GluN2A receptor expressed in Xenopus laevis oocytes assessed as inhibition of glutamate/glycine-induced channel current at 3 uM after 10 to 15 mins by two electrode voltage clamp based electrophysiology assay	two electrode voltage clamp based electrophysiology assay	B
1734787	Agonist activity at human kappa opioid receptor expressed in HEK293 assessed as inhibition forskolin-induced cAMP accumulation at 1 uM after 15 mins in presence of U50,488 by EIA	EIA	F
1735937	Inhibition of human PIP5K2C expressed in mammalian expression system assessed as remaining enzyme activity at 10 uM by kinome scan assay	kinome scan assay	B
1736751	Downregulation of CXCL2 mRNA expression level in human MONO-MAC-6 cells at 5 uM incubated for 30 mins measured after 2 hrs by qRT-PCR method relative to control	qRT-PCR method	F
1737421	Displacement of [125I]CCK-8s from human recombinant CCK1 receptor at 10 uM after 60 mins by scintillation counting analysis relative to control	scintillation counting analysis	B
1737901	Inhibition of EZH2 (unknown origin) at 33 uM relative to control		B
1739254	Antioxidant activity assessed as ferric ion reducing activity by measuring Fe2+ levels at 10 uM using Fe2+-TPTZ after 15 mins by FRAP assay	FRAP assay	F
1740028	Inhibition of wild-type BRAF (unknown origin) at 1 uM relative to control		B
1741239	Binding affinity to wild-type human full length DYRK2 (M1 to S528 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1741481	Binding affinity to wild-type human partial length PRKCI (H215 to V587 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1742172	Inhibition of human MKK1 assessed as enzyme residual activity at 100 nM by radiometric filter binding assay relative to control	radiometric filter binding assay	B
1743583	Inhibition of human EPHB1 (565 to 984 residues) assessed as residual activity at 500 nM in presence of 33P-ATP by filter binding assay relative to control	filter binding assay	B
1743774	Inhibition of recombinant human full length N-terminal GST-tagged MST1 expressed in baculovirus infected Sf9 cells assessed as change in enzyme activity at 1 uM in presence of 1 uM ATP relative to control		B
1745604	Inhibition of human Nav1.7 expressed in CHO-K1 cells at -120 mV holding potential incubated over 5 mins measured at 15 secs interval by Qpatch clamp assay	Qpatch clamp assay	B
1746638	Inhibition of recombinant human full length N-terminal His6-tagged and N-terminal GST-tagged CDK5/p35 expressed in baculovirus Sf21 insect cells at 10 uM by filter binding radioactive ATP transferase assay relative to control	filter binding radioactive ATP transferase assay	B
1746680	Inhibition of recombinant human N-terminal/C-terminal His6-tagged PAK2 (3 to end residues) expressed in Escherichia coli at 10 uM by filter binding radioactive ATP transferase assay relative to control	filter binding radioactive ATP transferase assay	B
1747422	Binding affinity to recombinant full length human N-terminal GST-tagged Syk-KD (356 to 635 residues) cytoplasmic domain expressed in baculovirus infected Sf9 insect cells using poly EY 4:1 as substrate		B
1747466	Antagonist activity at recombinant human eGFP-fused Ahr expressed in yeast cells co-expressing ARNT assessed as inhibition of benzo(a)pyrene-induced Ahr activation at 1 uM measured after 18 hrs by fluorescence assay	fluorescence assay	B
1750677	Binding affinity to human partial length BRD3 bromodomain 2 (G306 to P416 residues) expressed in bacterial expression system by BROMOscan assay	BROMOscan assay	B
1750933	Binding affinity to wild-type human partial length BMPR1A (Q214 to I532 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1751032	Binding affinity to wild-type human partial length EPHB3 (Q599 to T928 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1751186	Binding affinity to wild-type human partial length NEK9 (P32 to R328 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1751313	Binding affinity to wild-type human partial length TAOK2 (M1 to A320 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1751447	Displacement of TNP-ATP from recombinant Salmonella typhimurium GST-tagged DHp-catalytic domain PhoQ (332 to 487 residues) expressed in Escherichia coli XA90 aafter 10 mins by fluorescence assay	fluorescence assay	B
1755636	Inhibition of human TRPM8		B
1757987	Displacement of [3H]-GR65630 from human 5-HT3 receptor expressed in HEKT cells after 90 mins by microbeta scintillation counting analysis	microbeta scintillation counting analysis	B
1759988	Growth inhibition of Candida albicans at 32 ug/ml		F
1760563	Inhibition of recombinant human N-terminal His-tagged BAZ2B (1 to 913 residues) expressed in Escherichia coli at 10 uM relative to control		B
1765481	In-vivo binding affinity to transthyretin in beagle dog serum assessed as protein occupancy 5 mg/kg/day dosed daily dosed as single administration via oral gavage		F
1767769	Displacement of FAM-labeled HIF-1alpha peptide from VBC (unknown origin) by fluorescence polarization assay	fluorescence polarization assay	B
1769009	Inhibition of Xanthine oxidase (unknown origin) using xanthine as substrate preincubated for 1 to 5 mins followed by substrate addition		B
1770851	Binding affinity to Staphylococcus aureus genomic DNA at pH 7.4 at 294 K by fluorescence quenching analysis	fluorescence quenching analysis	B
1773499	Antifungal activity against Candida albicans ATCC 90028 infected in Galleria mellonella larvae infected with 20 uM compound pre-treated cell suspensions assessed as melanization incubated in dark for 144 hrs at 30 degC and measured every 24 hrs (Rvb = 65%)		F
1773592	Binding affinity to wild-type human partial length ARK5 (E25 to I332 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1773600	Binding affinity to wild-type human partial length BLK (G211 to L503 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1773635	Binding affinity to wild-type human partial length CDK8 (M1 to T360 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1773707	Binding affinity to wild-type human full length ERK2 (M1 to S360 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1773879	Binding affinity to wild-type human full length PHKG1 (M1 to Y387 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1774008	Binding affinity to wild-type human partial length ULK2 (M1 to S301 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1774531	Inhibition of recombinant GST-tagged human PDE9A2 expressed in insect cells using cGMP as substrate after 1 hr by IMAP TR-FRET assay	IMAP TR-FRET assay	B
1775920	Inhibition of full length human MARK3 (M1 to L729 residues) expressed in bacterial expression system assessed as residual activity at 5 uM by KINOMEscan assay relative to control	KINOMEscan assay	B
1778345	Inhibition of CLK3 (unknown origin)		B
1778489	Binding affinity to partial length human PDGFRA (V575 to D1002 residues) expressed in mammalian expression system by KdELECT assay	KdELECT assay	B
1778761	Potency index, ratio of cefaclor MIC to compound MIC for methicillin-resistant Staphylococcus aureus NRS70		F
1785169	Inhibition of INSR (unknown origin) at 30 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	mobility shift assay	B
1787146	Binding affinity to dopamine D3 receptor (unknown origin) assessed as inhibition of radioligand binding by radioligand competition binding assay		B
1787702	Potentiation of erythromycin-induced antibacterial activity against Enterococcus faecium ATCC 700221 assessed as minimum modulatory concentration up to 32 uM measured after 16 hrs in presence of MIC/4 erythromycin		F
1789168	Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 10 uM after 72 hrs by annexin-V/propidium iodide double staining based flow cytometry (Rvb = 0.02%)	annexin-V/propidium iodide double staining based flow cytometry	F
1790107	Antibacterial activity against Staphylococcus epidermidis clinical isolate incubated for 16 hrs under shaking condition		F
1792441	Binding affinity to human partial length KIT V559D/V654A double mutant (Y545 to D952 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	Kinomescan method	B
1792490	Binding affinity to wild-type human partial length MLK3 (I77 to W399 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	Kinomescan method	B
1792559	Binding affinity to wild-type human partial length PIKFYVE (F1512 to C2098 residues) expressed in mammalian expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	Kinomescan method	B
1792617	Binding affinity to wild-type human partial length N-terminal RSK4 kinase domain 1 (M1 to E397 residues) expressed in mammalian expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	Kinomescan method	B
1794453	Inhibition of recombinant human N-terminal His6-tagged full length FYN expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control		B
1795430	Antibacterial activity against Arcobacter butzleri after 17 hrs by NCCLS broth microdilution method	NCCLS broth microdilution method	F
1795953	Inhibition of recombinant human full length His-tagged Aurora A expressed in baculovirus expression system using peptide substrate after 1 hr by Z'-Lyte assay	Z'-Lyte assay	B
1797285	Binding affinity to human langerin expressed in human Raji cells preincubated with Cy5 conjugated compound for 2 hrs followed by washing and measured by flow cytometric analysis	flow cytometric analysis	B
1798774	Antioxidant activity assessed as carbon-centered lipid radical scavenging activity in presence of t-butylalcohol solvent		F
1798872	Cytotoxicity in human NCI-H446 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	MTT assay	F
1799294	Bactericidal activity against methicillin-sensitive Pseudomonas aeruginosa PAO1 at 400 uM after 18 hrs by resazurin-dye based fluorescence assay	resazurin-dye based fluorescence assay	F
1801095	Inhibition of basal ATPase activity of N-terminal His6-tagged human Eg5 motor domain (1 to 368 residues) expressed in Escherichia coli BL21 (DE3) by pyruvate kinase-lactate dehydrogenase coupled assay	pyruvate kinase-lactate dehydrogenase coupled assay	B
1802989	Binding affinity to human His-tagged MOF by SPR analysis	SPR analysis	B
1805757	Binding affinity to wild-type human partial length PDGFRA (V575 to D1002 residues) expressed in mammalian expression system assessed as enzyme remaining activity at 1 uM by Kinomescan assay relative to control	Kinomescan assay	B
1806100	Displacement of biotinylated AVPF from N-terminal His tagged recombinant human XIAP-BIR3 Lys311Ser mutant expressed in Escherichia coli BL21(DE3) cells incubated for 8 hrs by DELFIA	DELFIA	B
1807970	Inhibition of HDAC10 (unknown origin) using Ac-ArgThr- Lys(Ac)Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	fluorescence based assay	B
1808537	Binding affinity to wild-type human partial length MARK1 (Q30 to T341 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	Kinomescan method	B
1809282	Displacement of [3H]-Nisoxetine from human recombinant NET receptor expressed in stable HEK cells after 90 mins by microbeta scintillation counting method	microbeta scintillation counting method	B
1809315	Displacement of [3H]-Win35428 from human recombinant DAT receptor expressed in stable HEK cells at 10 uM after 90 mins by microbeta scintillation counting method relative to control	microbeta scintillation counting method	B
1814455	Inhibition of recombinant His-tagged human FGFR1 (308 to 731 resides) expressed in baculovirus expression system at 0.5 uM using tyr 04 as substrate in presence of ATP at Km concentration after 1 hr by Z'-LYTE assay relative to control	Z'-LYTE assay	B
1816940	Binding affinity to recombinant human carbonic anhydrase 13 expressed in Escherichia coli expression system assessed as kinetic gibbs free energy change by ITC method	ITC method	B
1825833	Inhibition of recombinant human full-length N-terminal His6-tagged Src expressed in Sf21 insect cells at 1000 nM using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA relative to control	ELISA	B
1829129	Inhibition of recombinant human full-length N-terminal His-tagged Tdp1 expressed in Escherichia coli BL21		B
1829280	Inhibition of IDH1 R132C mutant in human HT1080 cells assessed as inhibition of 2HG production after 48 hrs by LC-MS/MS analysis	LC-MS/MS analysis	B
1829544	Binding affinity to LSD1 (unknown origin)		B
1831311	Induction of multi-nuclei formation in mouse LL/2 cells at 0.8 uM after 24 hrs in presence of paclitaxel by 4',6-diamidino-2-phenylindole staining-based assay	4',6-diamidino-2-phenylindole staining-based assay	F
1833370	Binding affinity to wild-type human partial length EPHA3 (D604 to K889 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1833461	Binding affinity to wild-type human partial length LYN (C219 to Q511 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1833493	Binding affinity to wild-type human full length MKNK1 (M1 to L424 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1836348	Antibacterial activity against carbapenem-resistant Escherichia coli BAA-2469 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay	CLSI-based broth microdilution assay	F
1839334	Modulation of M2 polarization in mouse RAW264.7 cells assessed as up regulation of PPARGC1A mRNA expression at 300 nM measured after 24 hrs by qRT-PCR analysis	qRT-PCR analysis	F
1842485	Inhibition of EGFR T790M mutant (unknown origin)		B
1842749	Displacement of (+)-[3H]pentazocine from sigma1 receptor in guinea pig brain membranes		B
1843592	Cytotoxicity against human HeLa 229 cells measured after 48 hrs by MTT assay	MTT assay	F
1844213	Induction of apoptosis in human HCT116 cells assessed as viable cells at 0.5 uM by Annexin-V FITC/propidium iodide staining-based flow cytometry (Rvb = 93.4 %)	Annexin-V FITC/propidium iodide staining-based flow cytometry	F
1844860	Displacement of 6N-FAM from human LRH1 LBD (299 to 541 residues) expressed in Escherichia coli BL21 pLysS by competitive binding based fluorescence polarization assay	fluorescence polarization assay	B
1844861	Displacement of 6N-FAM from SF1 LBD (218 to 461 residues) (unknown origin) expressed in Escherichia coli BL21 pLysS by competitive binding based fluorescence polarization assay	fluorescence polarization assay	B
1845612	Potency index, ratio of [Nle15]MG11 IC50 to test compound IC50 for displacement of [177Lu] PP-F11N from CCK2R (unknown origin) transfected in A431 cells incubated for 1 hr at 4 degree C followed by compound washout with PBS buffer using Lu3+ labeled compound by Cobra-2 gamma counter method	Cobra-2 gamma counter method	B
1846866	Antiproliferative activity against human HL7702 cells assessed as reduction in cell viability after 48 hrs by MTT assay	MTT assay	F
1848946	Inhibition of cSRC (unknown origin)		B
1849706	Inhibition of PHGDH-mediated serine synthesis in human Carney cells in serine free medium at 40 uM preincubated for 1 hr followed by 13C6 labelled glucose addition and measured after 2 hrs by LC/MS analysis based 13C6-Glucose tracing assay relative control	LC/MS analysis	B
1851040	Binding affinity to human partial length TRIM33 (D882 to A1087 residues) expressed in bacterial expression system at 1 uM by BROMOscan assay	BROMOscan assay	B
1853595	Induction of cell cycle arrest in human HCT116 cells assessed as debris content at 0.7 uM incubated for 24 hrs by PI staining based flow cytometric analysis (Rvb = 0%)	PI staining based flow cytometric analysis	F
1855714	Inhibition of human TLR7 expressed in mouse RAW264.7 cells assessed as resiquimod-induced NO production at > 5 uM incubated for 18 to 24 hrs		B
1857117	Binding affinity to wild-type human full length DYRK2 (M1 to S528 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1857182	Binding affinity to wild-type human full length GRK3 (M1 to L688 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1857287	Binding affinity to wild-type human partial length NEK10 (L488 to R809 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1857915	Activity at human OX1 receptor up to 10 uM		B
1862272	Antiinflammatory activity in Wistar albino rat assessed as reduction in carrageenan-induced paw volume at 12.5 mg/kg, ip measured after 1 hr by plethysmometric method (Rvb = 1.43 +/- 0.19 ml)	plethysmometric method	F
1864044	Displacement of [3H]4-DAMP from recombinant human M3 receptor after 60 mins by scintillation counting analysis	scintillation counting analysis	B
1864118	Inhibition of human recombinant full length N-terminal GST tagged p38alpha expressed in baculovirus infected Sf9 cells using p38 peptide as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	ADP-Glo kinase assay	B
1864995	Inhibition of wild-type human partial length SIK (M1 to Y304 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	Kinomescan method	B
1865723	Inhibition of PKA (unknown origin) at 1 uM relative to control		B
1867223	Cytotoxicity against human HCT116 cells afte r18 hrs by MTT assay	MTT assay	F
1868563	Induction of morphological changes in human HeLa cells assessed as swollen cells at IC50 after 24 hrs by phase contrast microscopic analysis	phase contrast microscopic analysis	F
1869472	Inhibition of recombinant human LSD1 (172 to 852 residues) using biotin-labelled H3K4me2 (1 to 24 residues) after 1 hr by TR-FRET assay	TR-FRET assay	B
1869875	Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 2.5 uM after 12 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 7.19%)	Annexin V-FITC/propidium iodide staining-based flow cytometric analysis	F
1870082	Agonist activity at GAL4 DNA binding domain fused glucocorticoid receptor ligand binding domain (unknown origin) at 0.25 to 25 uM by FRET-based assay	FRET-based assay	B
1870247	Binding affinity to ABL2 in SILAC-labeled human MDA-MB-231 cells lysate by mass spectrometry based kinAffinity assay	mass spectrometry based kinAffinity assay	B
1870590	Mixed-type inhibition of human GAT1 expressed in COS cells assessed as reduction in [2H6]GABA uptake by measuring [2H6]GABA Km(app) at 300 nM preincubated for 25 mins followed by [3H]GABA addition and measured after 4 mins by liquid scintillation counting method (Rvb = 12 +/- 1.2 uM)	liquid scintillation counting method	B
1873995	Activation of YFP-tagged TLR2 (unknown origin) expressed in HEK293 cells assessed as induction of IL8 secretion at 8 ug/mL incubated for 16 to 18 hrs by ELISA	ELISA	B
1874045	Binding affinity to human partial length PIK3CA E545A mutant (R108 to N1068 residues) expressed in mammalian expression system measured after 1 hr by kinomescan method	kinomescan method	B
1876338	Inhibition of recombinant human cKit (544 to end residues) at 1 uM using using Poly(Glu,Tyr) 4:1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	scintillation counting method	B
1876505	Inhibition of recombinant human IRAK1 (194 to end residues) at 1 uM using myelin basic protein as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	scintillation counting method	B
1877072	Displacement of fluorescein labelled Puma-BH3 peptide from His-tagged-TEV fused human Mcl-1 incubated for 2 hrs by fluorescence polarization assay	fluorescence polarization assay	B
1877750	Inhibition of human recombinant ASK1 (649 to 946 residues) using myelin as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	radiometric scintillation counting analysis	B
1878057	Inhibition of recombinant full-length human STK33 using myelin basic protein as substrate incubated for 40 mins in presence of [gamma33P]ATP by radiometric scintillation counting analysis	radiometric scintillation counting analysis	B
1880923	Binding affinity to wild-type human partial length CAMKK1 (R65 to E414 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1880975	Binding affinity to wild-type human full length DRAK2 (M1 to C372 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1881035	Binding affinity to wild-type human partial length autoinhibited FLT3 (H564 to Y969 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1881441	Inhibition of GGPPS in human RPMI8226 cells assessed as induction of ER-stress induced XBP1 mRNA splicing at 100 to 1000 nM by RT-PCR analysis	RT-PCR analysis	B
1881838	Displacement of [3H]CP 55940 from human recombinant CB1 receptor at 10 uM after 120 mins by scintillation counting analysis relative to control	scintillation counting analysis	B
1887987	Inhibition of wild-type human partial length DDR1 (R565 to V876 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1889510	Binding affinity to wild-type human partial length CHEK1 (M1 to G289 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	Kinomescan method	B
1889540	Binding affinity to wild-type human partial length DMPK2 (S46 to S408 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	Kinomescan method	B
1889827	Binding affinity to wild-type human partial length SBK1 (P23 to P348 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	Kinomescan method	B
1889839	Binding affinity to wild-type human full length SRPK1 (M1 to S655 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	Kinomescan method	B
1890195	Antialzhemeric activity in Wistar rat model of scopolamine-induced cognition deficit assessed as effect on time in target sector at 100 nM, icv dosed 60 mins prior to training trial by Morris water maze test	Morris water maze test	F
1892894	Antagonist activity at D4 receptor (unknown origin)		B
1894049	Inhibition of human topoisomerase-2alpha assessed as rate of ATP hydrolysis at 50 uM using pBR322 as substrate measured up to 30 mins in presence of 0.05 mM ATP by pyruvate kinase/lactate dehydrogenase enzyme coupled assay (Rvb = 0.238 to 0.559 microM/min)	pyruvate kinase/lactate dehydrogenase enzyme coupled assay	B
1895739	Selectivity ratio of ki for muscarinic M4 receptor (unknown origin) expressed in CHO cells to muscarinic M2 receptor (unknown origin) expressed in CHO cells		B
1898090	Inhibition of human activated protein C		B
1898332	Inhibition of PDK2 in human MG63 cells assessed as reduction in lactate formation at 2 to 10 uM incubated for 4 hrs		B
1899144	Inhibition of CMFDA binding to human N-terminal 6x-His-tagged GSTO1-1 at 10 uM preincubated for 30 mins followed by CMFDA addition and measured after 30 mins in presence of 10 uM MnCl2 by in-gel fluorescence binding assay	in-gel fluorescence binding assay	B
1903361	Inhibition of wild-type human partial length SYK (D354 to N635 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	Kinomescan method	B
1904292	Inhibition of human testis ACE C-domain lacking unique O-glycosylated region, transmembrane anchor and cytoplasmic tail expressed in CHO cells using Z-FHL as substrate by fluorescence based assay	fluorescence based assay	B
1904958	Displacement of [3H]ZM241385 from recombinant human A2A receptor incubated for 90 mins under dark condition by microbeta scintillation method	microbeta scintillation method	B
1905613	Inhibition of recombinant human cRaf (306 to end residues) at 1 uM using unactive MEK1 as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	scintillation counting method	B
1907990	Induction of YqiG protein expression in Bacillus subtilis 168 at 2.3 uM incubated for 15 mins by 35S-methionine pulse labeling based 2D-PAGE analysis	35S-methionine pulse labeling based 2D-PAGE analysis	F
1908752	Covalent binding affinity to human GRK5 assessed as covalent bond formation with Cys474 by intact protein mass spectrometry	intact protein mass spectrometry	B
1911716	Inhibition of recombinant human GST-tagged CK2alpha at 10 uM in presence of ATP by radiometric kinase assay relative to control		B
1912425	Binding affinity to wild-type TTR (unknown origin) assessed as induction of chemical shift at L58 residue at 0.6:1 to 1:1 ratio of compound to protein by 2D TROSY [1H-15N] spectroscopy	2D TROSY [1H-15N] spectroscopy	B
1921222	Binding affinity to HIV1 cYTA48P envelope glycoprotein gp120 infected in human TZM-b1 cells assessed as induction of conformational changes by measuring combination index at 450:1 ratio of test compound to KD-247 measured after 48 hrs		B
1921767	Inhibition of MAGL in human U937 cell homogenates incubated for 5 mins in presence of [1,2,3-3H]2-OG by liquid scintillation spectroscopy	liquid scintillation spectroscopy	B
1923667	Binding affinity to zanamivir/oseltamivir resistant recombinant Influenza A virus (A/Moscow/10/99(H3N2)) Neuraminidase N2 E119V/I222L double mutant expressed in baculovirus infected insect cells assessed as dissociation rate constant measured up to 400 sec by surface plasmon resonance analysis	surface plasmon resonance analysis	B
1925887	Binding affinity to pre-annealed c-MYC G-quadruplex (unknown origin) in 10 mM Tris.HCl buffer containing 100 mM KCl at pH 7.4 by UV/Visible spectroscopy	UV/Visible spectroscopy	B
1928208	Inhibition of EGFR (unknown origin) at 20 nM relative to control		B
1928863	Cytotoxicity against human A549 cells assessed as cell survival up to 10 uM incubated for 24 hrs by CCK8 assay	CCK8 assay	F
1929767	Binding affinity to calf thymus duplex DNA assessed as induction of hyperchromic shift at 257 nanometer at 50 uM in pH 7 phosphate buffer by UV-vis spectrophotometric analysis	UV-vis spectrophotometric analysis	B
1929784	Binding affinity to calf thymus duplex DNA assessed as induction of ellipticity at 25 to 200 uM in pH 8.9 phosphate buffer by circular dichroism method	circular dichroism method	B
1930260	Displacement of [3H]diprenorphine from rat delta opioid receptor expressed in rat C6 cell membranes measured after 1 hr by liquid scintillation counting method	liquid scintillation counting method	B
1930399	Antiviral activity against wild-type HIV1 NL4-3 infected infected in human MT2 cells assessed as reduction in extracellular RNA at 1 uM and measured after 30 hrs post infection by Alu-LTR PCR protocol based method	Alu-LTR PCR protocol based method	F
1930475	Agonist activity at human LXRalpha transfected in HepG2 at 10 uM by luciferase reporter assay	luciferase reporter assay	B
1931928	Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of croton oil-induced ear edema at 15 mg/kg, ip administered 1 hr before croton oil challenge measured after 3 hrs post challenge relative to control		F
1934860	Inhibition of human biotinylated VEGF-A165 binding to recombinant human NRP1 receptor at 100 uM after 2 hrs by chemiluminescence analysis relative to control	chemiluminescence analysis	B
1935982	Anti-inflammatory activity in Wistar (Krf:(WI) WU) rat model of carrageenan-induced thermal hyperalgesia assessed as paw withdrawal latency time at 50 mg/kg, ip administered as single dose prior to carrageenan challenge and measured after 2 hrs by plantar test (Rvb = 4.03 +/- 0.7 s)	plantar test	F
1971164	Binding affinity to IDH1 R132C mutant (unknown origin) by mass spectrometry	mass spectrometry	B
1979354	Binding affinity to human partial length BRDT bromodomain 1 (N21 to E137 residues) expressed in bacterial expression system by BROMOscan assay	BROMOscan assay	B
1983677	Binding affinity to SOX2 promoter 5'-CTTTGTT-3' DNA in mouse Hepa1 cells assessed as reduction in SOX2 mRNA expression incubated for 48 hrs by qRT-PCR analysis	qRT-PCR analysis	B
1984949	Antiinflammatory activity in mouse T cells assessed as inhibition of conA-induced induced T cell proliferation at 2 uM incubated for 48 hrs by CCK8 assay relative to control	CCK8 assay	F
1985872	Inhibition of MYST2 (unknown origin)		B
1987633	Anti-urolithic activity in synthetic urine assessed as decrease in absorbance at 10 mg/mL relative to control		F
1991216	Antagonist activity at human VDR transfected in HEK293T cells measured after 24 hrs by luciferase reporter gene assay	luciferase reporter gene assay	B
1991217	Agonist activity at human FXR expressed in human HuH7 cells by luciferase reporter gene assay relative to control	luciferase reporter gene assay	B
1991288	Ratio of Ki for displacement of [3H]DPCPX from Sprague-Dawley rat whole brain membrane A1AR in presence of GTP to Ki for displacement of [3H]DPCPX from Sprague-Dawley rat whole brain A1AR		B
1991397	Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylation of RAF measured after 24 hrs by Western blot analysis	Western blot analysis	B
1992205	Binding affinity to BLM in human HCT116 cells cotransfected with DSB model and I-SceI plasmid assessed as reduction in recruitment of protein to DSB site in DNA at 1 uM measured after 24 hrs by chromatin immunoprecipitation assay	chromatin immunoprecipitation assay	B
1996342	Displacement of [125I]-NDP-alpha-MSH from human MC4R expressed in CHO-K1 cell membranes incubated for 3 hrs by top-count beta counting relative to control	top-count beta counting	B
2013313	Cytotoxicity against human SK-MEL-28 cells assessed as cell viability at 10 uM incubated for 48 hrs by sulforhodamine B assay relative to control	sulforhodamine B assay	F
2013398	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system using Tyr 01 as substrate at 0.1 uM incubated for 60 mins by Z'-Lyte assay relative to control	Z'-Lyte assay	B
2014877	Binding affinity to C-terminal 8-His tagged human MMP-9 hemopexin-like domain (Ala20 to Asp707 residues) expressed in 293E cells by fluorescence spectroscopy	fluorescence spectroscopy	B
2017246	Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells assessed as ratio of Kinact to Ki measured after 1 to 24 hrs by fluorescence assay	fluorescence assay	B
2017553	Displacement of [125I]+/-DOI from human recombinant 5-HT2B receptor at 10 uM after 60 mins by scintillation counting analysis relative to control	scintillation counting analysis	B
2019174	Antiviral activity against ETV-resistant and adenovirus AdH294-7LR harboring wild-type HBV infected in human HepG2 cells assessed as reduction in viral replicative intermediate DNAs at 4 to 1000 nM incubated for 5 days by Southern blot analysis	Southern blot analysis	F
2023321	Antiproliferative activity against human HUT78 assessed as reduction in cell viability incubated for 3 days by Cell Titer Blue assay	Cell Titer Blue assay	F
2029444	Induction of autophagy in human DLD-1 cells assessed as vacuole formation at 7.5 uM incubated for 24 hrs in presence of Bafilomycin-A1 by phase contrast microscopic analysis	phase contrast microscopic analysis	F
2032025	Inhibition of human COX2 assessed as reduction in PGF2alpha formation using arachidonic acid as substrate incubated for 10 mins by ELISA	ELISA	B
2049002	Antifungal activity against Candida albicans ATCC 90028 assessed as reduction in microbial growth after 18 to 24 hrs by CLSI based method	CLSI based method	F
2049841	Inhibition of GST-tagged recombinant PDGFRbeta (unknown origin) expressed in baculovirus expression system incubated for 15-45 mins in presence of [gamma32P]-ATP by radiometric assay		B
2051018	Binding affinity to DAT (unknown origin) assessed as inhibition of ligand binding at 10 uM relative to control		B
2052178	Inhibition of HDAC1 in human HeLa nuclear extract using Boc-Lys(Ac)-AMC as substrate measured after 2 hrs by fluorescence based assay	fluorescence based assay	B
2052717	Binding affinity at Escherichia coli pBR322 DNA assessed as unwinding of supercoiled DNA at 10 uM incubated for 10 mins in presence of human topoisomerase 1 by agarose gel based electrophoresis	agarose gel based electrophoresis	B
2053483	Inhibition of IDH2 R172K mutant (unknown origin) assessed as reduction in NADPH consumption using alpha-ketoglutarate and NADPH as substrate preincubated with enzyme for 15 mins followed by substrate addition by fluorescence based assay	fluorescence based assay	B
2054653	Induction of ROS-mediated apoptosis in human SGC-7901 cells assessed as early apoptotic cells at 1 uM incubated for 48 hrs by annexin V-PE and 7-AAD staining based flow cytometry analysis (Rvb = 1.89 %)	annexin V-PE and 7-AAD staining based flow cytometry analysis	F
2054967	Antiallodynic activity in oxaliplatin-induced peripheral neuropathy pain CD-1 mouse model assessed as inhibition of late-phase tactile allodynia by measuring pain sensitivity threshold at 22.5 mg/kg administered with compound intraperitoneally at 7 days after oxaliplatin stimulation and measured after 30 mins by von Frey test (Rvb = 65.3%)	von Frey test	F
2058599	Inhibition of ALK in human NCI-H3122 cells assessed as downregulation of AKT expression levels at 10 to 500 nM incubated for 24 hrs by western blot analysis	western blot analysis	B
2059816	Inhibition of 5-(3-((1r,4r)-4-((5S,8S,11S,14S,17S,20S,29S)-11-((1H-imidazol-4-yl)methyl)-1,33-diamino-5-carbamoyl-17-(4-(4-(4-((4-(dimethylamino)phenyl)diazenyl)phenyl)butanamido)butyl)-8,14-bis(3-guanidinopropyl)-20-methyl-7,10,13,16,19,22,25,28-octaoxo-6,9,12,15,18,21,24,27-octaazatritriacontan-29-ylcarbamoyl)cyclohexyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid binding to SIRT2 (unknown origin) measured after 2 hrs in presence of NAD+ by fluorometric method	fluorometric method	B
2062261	Inhibition of N-terminal GST-tagged human FLT4 (800 to end residues) expressed in baculovirus infected Sf21 cells assessed as residual activity at 10 uM relative to control		B
2063770	Inhibition of His-tagged PTPmu (unknown origin) expressed in Escherichia coli BL21 cells using para-nitrophenyl phosphate as substrate incubated for 5 to 10 mins by microplate reader based spectrophotometric analysis	spectrophotometric analysis	B
2064349	Antiviral activity against HCV J6/JFH/JC1 harboring D168V mutant infected in human Huh7.5 cells assessed as inhibition of viral replication measured after 72 hrs by qRT-PCR analysis	qRT-PCR analysis	F
2065931	Inhibition of human ALK3 assessed as residual activity using casein as substrate at 1 uM by [gamma-33P]-ATP assay relative to control		B
2066315	Inhibition of wild-type human partial length ULK1 (M1 to T309 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Kinomescan method	B
2067582	Induction of apoptosis in human HCC827 cells assessed as early apoptotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 2.49%)	Annexin V-FITC/propidium iodide staining based flow cytometry	F
2068291	Displacement of [3H]DTG from sigma 2 receptor in rat PC12 cells incubated for 120 mins in presence of [3H]-(+)-pentazocine by liquid scintillation counting method	liquid scintillation counting method	B
2069197	Binding affinity to HPGDS (unknown origin) assessed as change in melting temperature by thermal shift assay	thermal shift assay	B
2069435	Displacement of (1-(2-aminoethyl)-3,5-dimethyl-1H-pyrazol-4-yl)(4-((1-neopentyl-1H-benzo[d]imidazol-2-yl)methyl)piperazin-1-yl)methanone from FNTA in vorinostat-stimulated human Jurkat 2C4 cells infected with latent HIV-1 by pull-down experiment based competitive binding assay	pull-down experiment based competitive binding assay	B
2069831	Agonist activity at human RXRalpha transfected in human HEK293T cells co-expressing pFR/pRL-Luc at 30 uM incubated for 14 to 16 hrs by hybrid reporter gene assay relative to bexarotene	hybrid reporter gene assay	B
2069991	Inhibition of human HIPK2 assessed as remaining enzyme activity at 1 uM		B
2070437	Inhibition of MEK5 (unknown origin)		B
2072747	Binding affinity to CLK4 (unknown origin)		B
2073738	Negative allosteric modulator activity at human PDE5A1 (535-860 residues) expressed in Escherichia coli BL21 assessed as Kcat for cGMP at 50 nM incubated for 15 mins using [3H]-cGMP as substrate by liquid scintillation counting method (Rvb = 2.53 +/- 0.24 /s)	liquid scintillation counting method	B
2074736	Displacement of [3H]CP55940 from human CB1R transfected in HEK293EBNA cell membranes incubated for 90 mins by Microbeta TriLux based luminescence analysis	Microbeta TriLux based luminescence analysis	B
2074786	Displacement of FITC-WFYpSPFLE from human Pin1 (45-163) catalytic domain by fluorescence polarization assay	fluorescence polarization assay	B
2076539	Induction of eNOS phosphorylation in FFA-induced oxidatively stress human HepG2 cells by Western blot analysis relative to control	Western blot analysis	B
2076633	Activation of FoxO3A in human MDA-MB-231 cells after 72 hrs by immunoblot analysis	immunoblot analysis	B
2079764	Displacement of [3H]-LSD from human 5HT6 receptor expressed in HEK293 cell membrane at 10^-6 M measured after 60 mins relative to control		B
2081167	Inhibition of human CAH14 expressed in Escherichia coli BL21 (DE3) by stopped flow CO2 hydration assay	stopped flow CO2 hydration assay	B
2081184	Inhibition of CAH9 in human UFH-001 cells under normoxic condition by membrane inlet for mass spectrometry	membrane inlet for mass spectrometry	B
2085047	Displacement of [3H]-(S)-2-(6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)biphenyl-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid from human recombinant full-length GPR40 expressed in human HEK293 cell membrane assessed as Koff rate measured after 2 hrs by radioligand competitive assay		B
2085469	Inhibition of recombinant human CK1delta (1 to 294 residues) assessed as residual activity at 10 uM using KRRRALS(p)VASLPGL as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	scintillation counting	B
2086338	Inhibition of His-tagged full length human CHK1 expressed in baculovirus expression system at 1 uM by Selectscreen kinase assay		B
2086797	Inhibition of Aurora A (unknown origin) incubated for 1 hrs by HTRF assay	HTRF assay	B
2087246	Activation of NAE1-mediated neddylation in human MGC-803 cells assessed as increase in Nedd8-Ubcl2 adduct formation at 50 to 150 nmol/L measured after 24 hrs by Western blot analysis	Western blot analysis	B
2087582	Inhibition of STAT5 phosphorylation in imatinib-resistant human K562 cells in presence of imatinib at 10 uM measured after 6 hrs by Western blot assay	Western blot assay	B
2088061	Induction of apoptosis in human A-375 cells assessed as necrotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.139 %)	annexin V-FITC and PI staining based flow cytometry	F
2088829	Inhibition of EGF-induced phosphorylation of EGFR L858R/T790M double mutant in human H1975 cells incubated for 2 hrs followed by EGF stimulation for 10 mins by western blot analysis	western blot analysis	B
2089693	Inhibition of recombinant human HDAC1 using Z-(Ac)Lys-AMC as substrate after 90 mins by fluorescence based micro plate assay	fluorescence based micro plate assay	B
2090202	Binding affinity to human full length N-terminal GST-tagged HDAC4 by surface plasmon resonance analysis	surface plasmon resonance analysis	B
2091862	Inhibition of BTK in human Ramos cells assessed as reduction in anti-human IgM F(ab)2-induced BTK phosphorylation at Tyr551 residue preincubated for 10 mins followed by stimulated with antihuman IgM F(ab)2 incubated for 60 mins by Western blot analysis	Western blot analysis	B
2092323	Inhibition of recombinant human N-terminal His-tagged HDAC11 expressed in baculovirus infected Sf9 insect cells using Ac-Arg-His-Lys(Ac)-Lys(Ac)-AMC as substrate measured after 30 mins by fluorescence assay	fluorescence assay	B
2093877	Inhibition of c-SRC (unknown origin)		B
2105132	Induction of cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at S phase at 4 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 40.37 to 57.89 %)	PI staining based flow cytometry analysis	F
2105425	Binding affinity to DNA Hoxa9-binding site-5'-ATTTA/5'ATGA double mutant (strand a-CTGCGTAGCGTCACGACCGC/strand b-GCGGTCGTGACGCTACGCAG) (unknown origin) by UV/visible spectrophotometric method	UV/visible spectrophotometric method	B
2108689	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	MTT assay	F
2109375	Inhibition of MALT1 in human Jurkat cells assessed as decrease in CYLD substrate cleavage by Western blotting analysis	Western blotting analysis	B
2112257	Inhibition of human TDO expressed in HEK293-EBNA cells assessed as reduction in kynurenine formation using tryptophan as substrate at 6.25 uM incubated for 24 hrs by HPLC analysis relative to control	HPLC analysis	B
2112640	Inhibition of N-terminal GST-tagged full length human HDAC6 expressed in baculovirus-infected Sf9 cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition and further incubated for 30 mins by fluorescence based assay	fluorescence based assay	B
2112908	Inhibition of BRD4-BD1 (unknown origin) preincubated for 15 mins followed by substrate addition and measured after 1 hr		B
2115142	Inhibition of CBP in human MOLM-13 cells assessed as reduction in H3K27Ac level at 3 uM incubated for 2 hrs by RT-PCR analysis	RT-PCR analysis	B
2115206	Gastroprokinetic activity in CD-1 mouse assessed as stimulation of gastrointestinal motility by measuring fecal number at 10 mg/kg, po measured after 2 hrs (Rvb = 5.3 +/-0.7 No_unit)	measuring fecal number	F
2118419	Inhibition of human CREBBP (A1040 to G1161 residues) at 10 uM by DiscoverX assay relative to control		B
2118948	Inhibition of human TLR7 in HEK-Blue hTLR7 cells assessed as reduction in gardiquimod-activated NF-KappaB by SEAP reporter assay	SEAP reporter assay	B
2119431	Inhibition of vanadate sensitive BCRP ATPase activity in human S1-M1-80 cell membranes preincubated for 30 mins followed by ATP addition and measured after 1 hr by colorimetric assay	colorimetric assay	B
2119620	Inhibition of recombinant human C-terminal His-tagged HDAC9 (604 to 1066 residues) expressed in baculovirus expression system using Nepsilon-Trifluoroacetyl L-lysine substrate by fluorescent microplate reader assay	fluorescent microplate reader assay	B
2121636	Inhibition of HDAC10 (unknown origin) at 0.5 uM relative to control		B
2122060	Binding affinity to human MAP3K2 at 1 uM by KINOMEscan scanMAX assay relative to control	KINOMEscan scanMAX assay	B
2123220	Positive allosteric modulator activity in mouse kappa opioid receptor stably expressed in HEK293 cell membrane assessed as binding affinity of dyn A1-13 to orthosteric binding site at 0.1 uM coincubated with dyn A1-13 for 90 mins by radioligand competition binding assay		B
2123529	Reversible inhibition of recombinant full length LSD1 (unknown origin) transfected in Escherichia coli BL21 (DE) assessed as enzyme recovery activity by jump dilution assay relative to control	jump dilution assay	B
2125288	Binding affinity to telomeric Htg24 G-quadruplex DNA G17A mutant (unknown origin) assessed as negative fluorescence signal at 5 uM under pH condition 7.4 by fluorescence titration analysis	fluorescence titration analysis	B
2130535	Binding affinity to human SIRT1 human MDA-MB-231 cells assessed as increase in thermal stability heated for 3 mins up to 1 degC at 10 uM by cellular thermal shift assay	cellular thermal shift assay	B
2131421	Inhibition of C-terminal 6-His-tagged beta-catenin (1 to 781 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3)-N-terminal biotinylated human BCL9 (350 to 375 residues) protein-protein interaction incubated for 1 hr by Alphascreen assay	Alphascreen assay	B
2132583	Displacement of [3H]-SCH23390 from D3 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method	microbeta scintillation counting method	B
2145610	Induction of apoptosis in mouse GL261 cells assessed as early apoptotic cells at 50 uM measured after 24 hrs by annexin V-FITC/propidium iodide staining based flow cytometry analysis (Rvb = 1.61%)	annexin V-FITC/propidium iodide staining based flow cytometry analysis	F
2146152	Antibacterial activity against Acinetobacter baumannii ATCC 17961 assessed as inhibition of bacterial growth after 16 hrs by two fold dilution method	two fold dilution method	F
2146163	Displacement of GDP-BODIPY probe from BTN3A1 full intracellular domain (unknown origin) at 0.1 mM measured after 60 mins by fluorescence polarization assay	fluorescence polarization assay	B
2149103	Binding affinity to Grb2-SH2 domain (unknown origin) by ELISA	ELISA	B
2150702	Inhibition of TrkC (unknown origin) by radiometric assay		B
2150721	Inhibition of TrKC (unknown origin) incubated for 120 mins in presence of 33P-ATP		B
2154276	Inhibition of human recombinant Mnk2 assessed as reduction in substrate phosphorylation at 50 to 500 nM using ATP and CREBtide (CKRREILSRRPSYRK) as substrate incubated for 90 min by LANCE detection method	LANCE detection method	B
2154913	Cytotoxicity against human Ramos cells assessed as cell death incubated at 10 uM for 20 hrs measured by DNS assay	DNS assay	F
2156446	NO releasing activity assessed as NO release efficiency at 100 uM by Griess assay relative to NaNO2	Griess assay	F
2157377	Positive allosteric modulator activity at human MRGPRX1 transfected in HEK293 cells in presence of BAM8-22 by Fulo4AM dye based FLIPR assay	Fulo4AM dye based FLIPR assay	B
2160336	Antitumour activity against human LNCaP cells xenografted in CB17 SCID mouse assessed as tumour growth inhibition at 2.5 mg/kg, IT(Intratumoral) administered once in every week for 25 days		F
2161850	Displacement of sphingosine D-erythro [3-3H] I- phosphate from human S1P2 receptor expressed in CHO cell membrane		B
2163697	Binding affinity to FGFR4 (unknown origin) assessed as dissociation constant by competition binding assay		B
2164646	Reactivation of NIMP-inhibited recombinant His-TEV-tagged human AChE expressed in CHO-K1 cells assessed as reactivation constant, Kr by measuring thiophenol levels by UV-vis absorption spectroscopy	UV-vis absorption spectroscopy	B
2168604	Antagonist activity at ERbeta (unknown origin) assessed as inhibition of fluorescein-labelled coactivator PGC1 peptide recruitment at 34 nM incubated for 30 mins by LanthaScreen TR-FRET assay relative to control	LanthaScreen TR-FRET assay	B
2170430	Antitumor activity against human Raji cells xenografted in NOD-SCID mouse assessed as tumor growth inhibition at 1.5 mg/kg, po administered for 25 days		F
2173021	Inhibition of DLK (unknown origin) at 1 uM		B
2184782	Inhibition of human recombinant HDAC6 using BML-AK511 as substrate incubated for 60 mins by fluorimetric assay	fluorimetric assay	B
2185625	Inhibition of N-terminal 6XHis-SUMO2 fused full length human cGAS (1 to 522 residues) expressed in human THP-1 cells transfected with HT-DNA incubated for 20 mins in presence of ATP by luminescence based analysis	luminescence based analysis	B
2187796	Binding affinity to N-terminal P62 (1 to 335 residues) in human HCT-116 cells lysates		B
2188161	Antiproliferative activity against human SNU-16 cells assessed as inhibition of cell proliferation incubated for 5 days by CCK-8 assay	CCK-8 assay	F
2192958	Cytotoxicity against human HT-29 cells incubated for 72 hrs by MTT assay	MTT assay	F
2193286	Noncompetitive inhibition of GOT1 (unknown origin) using aspartic acid and alpha-ketoglutaric acid as substrate incubated in presence of pyridoxal 5'-phosphate		B
2195904	Inhibition of UCHL1 in human HEK293 cells using HA-Ub-VME as substrate at 0.1 to 10 uM incubated for 1 hr by immunoblotting analysis	immunoblotting analysis	B
2196705	Inhibition of amyloid beta (1 to 42) (unknown origin) aggregation at 75 uM incubated for 1 hr by thioflavin-T fluorescence method	thioflavin-T fluorescence method	B
2196852	Inhibition of TRKB (unknown origin) in presence of [gamma33P]ATP by radiometric HotSpot assay	radiometric HotSpot assay	B
2197346	Binding affinity to D4 receptor (unknown origin) assessed as dissociation constant		B
2197502	Binding affinity to human recombinant 5-HT2A assessed as inhibition constant		B
2201141	Binding affinity to Bcl-XL (unknown origin)		B
2202607	Downregulation of MMP9 protein expression in human HepG2 cells at 25 to 50 uM incubated for 24 hrs by Western blot analysis	Western blot analysis	F
2204318	Inhibition of Abl T315I mutant (unknown origin) at 1 uM relative to control		B
2208145	Binding affinity to S1PR2 (unknown origin) by SPR assay	SPR assay	B
2208413	Antagonist activity at AMPA receptor (unknown origin)		B
2209071	Binding affinity to human recombinant ERbeta by competitive fluorometric binding assay	competitive fluorometric binding assay	B
2210648	Reversible inhibition of N-terminal His-tagged human recombinant glycolate oxidase expressed in Escherichia coli BL21 (DE3) cells assessed as enzyme recovery using glycolate as substrate at 100 times of IC50 concentration preincubated for 30 mins followed by substrate addition and measured every 60 sec for 15 mins by jump-dilution based Amplex red and horseradish peroxidase fluorescence assay	jump-dilution based Amplex red and horseradish peroxidase fluorescence assay	B
2210918	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	MTT assay	F
2214047	Antiproliferative activity against human A498 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	SRB assay	F
2214320	Antibiofilm activity against vancomycin-intermediate Staphylococcus aureus ATCC 700699 assessed as inhibition of biofilm formation incubated for 24 hrs by crystal violet staining based assay	crystal violet staining based assay	F
2221491	Inhibition of PKN2 (unknown origin) by TR-FRET-based tracer displacement assay dependent Cheng-Prusoff equation analysis	TR-FRET-based tracer displacement assay	B
2228192	Inhibition of human full length NSD2 at 10 uM by radioisotope-based filter binding assay	radioisotope-based filter binding assay	B
2229996	Antiproliferative against in mouse BaF3 EFGR Del19/T790M/C797S cell		F
2231389	Inhibition of BTK (unknown origin) at 1.0 uM relative to control		B
2231580	Binding affinity to PRDX6 in human MDA-MB-453 cells at 10 uM measured after 6 hrs in presence of 100 uM PES by pull-down assay	pull-down assay	B
2232845	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as bacterial growth inhibition incubated for 5 hrs under shaking condition by resazurin dye based assay	resazurin dye based assay	F
2235893	Covalent binding affinity to N-terminal His-Smt-tagged MSK1 C-terminal kinase domain (414 to 738 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) at 1:1 ratio of enzyme to compound measured after 3 hrs by LC-MS analysis relative to control	LC-MS analysis	B
2237671	Cytotoxicity against human LXFL 529 cells assessed as cell growth inhibition measured after 3 days by SRB assay	SRB assay	F
2244768	Inhibition of MAPK8 (unknown origin) at 50 nM by Z'LYTE screening method relative to control	Z'LYTE screening method	B
2248318	Binding affinity to His6-fused BRD3 BD2 (unknown origin) assessed as change in melting temperature at 100 uM incubated for 30 mins by thermal shift assay	thermal shift assay	B
2251008	Negative allosteric modulation activity against human ATX using FS-3 as substrate preincubated for 45 mins followed by substrate addition and measured every 30 mins by multi-mode microplate reader		B
2254352	Inhibition of N-terminal thioredoxin-His6 tagged human BCL6 BTB domain (5 to 129 residues) expressed in Escherichia coli BL21-AI incubated for 2 hrs by TR-FRET assay	TR-FRET assay	B
2254758	Binding affinity to 5-HT5A receptor (unknown origin) at 10000 nM by radioligand displacement assay relative to control		B
2260017	Binding affinity to TCP-stimulated NMDA (unknown origin)		B
2260695	Binding affinity to calf thymus DNA assessed as stabilization by measuring melting temperature at ratio of 0.2 by UV/vis spectrophotometric (Rvb = 66 degreeC)	UV/vis spectrophotometric	B
2261490	Inhibition of ABCG2 (unknown origin) overexpressing in dog MDCK-II-BCRP cells		B
2262115	Binding affinity to human Sirt3 (118 to 399 residues) assessed as dissociation constant (Koff) of ternary complex using acetylated MnSOD peptide as substrate in presence of OAADPr by short DNA nano levers based switchSENSE microfluid bio-chip analysis	short DNA nano levers based switchSENSE microfluid bio-chip analysis	B
